E2F-1	B-protein
blocks	O
terminal	O
differentiation	O
and	O
causes	O
proliferation	O
in	O
transgenic	B-cell_type
megakaryocytes	I-cell_type
.	O

The	O
transcription	B-protein
factor	I-protein
E2F-1	B-protein
plays	O
a	O
central	O
role	O
in	O
the	O
cell	O
cycle	O
through	O
its	O
ability	O
to	O
activate	B-DNA
genes	I-DNA
involved	O
in	O
cell	O
division	O
.	O

E2F-1	B-protein
activity	O
is	O
regulated	O
by	O
a	O
number	O
of	O
proteins	O
,	O
including	O
the	O
retinoblastoma	O
susceptibility	B-DNA
gene	I-DNA
product	O
,	O
cyclin-dependent	B-protein
kinases	I-protein
,	O
and	O
their	O
inhibitors	O
,	O
proteins	O
that	O
have	O
been	O
implicated	O
in	O
the	O
control	O
of	O
certain	O
developmental	O
processes	O
.	O

To	O
investigate	O
a	O
potential	O
role	O
of	O
E2F-1	B-protein
in	O
differentiation	O
,	O
we	O
assayed	O
the	O
ability	O
of	O
megakaryocytes	B-cell_type
to	O
form	O
platelets	B-cell_type
in	O
an	O
in	O
vivo	O
transgenic	O
model	O
.	O

E2F-1	B-protein
expression	O
in	O
megakaryocytes	B-cell_type
blocked	O
differentiation	O
during	O
maturation	O
,	O
resulting	O
in	O
severe	O
thrombocytopenia	O
.	O

Ultrastructural	O
analysis	O
of	O
megakaryocytes	B-cell_type
revealed	O
abnormal	O
development	O
characterized	O
by	O
hyperdemarcation	O
of	O
cytoplasmic	O
membranes	O
and	O
reduced	O
numbers	O
of	O
alpha	O
granules	O
.	O

Administration	O
of	O
megakaryocyte	B-protein
growth	I-protein
and	I-protein
development	I-protein
factor	I-protein
or	O
interleukin	B-protein
6	I-protein
could	O
not	O
overcome	O
the	O
differentiation	O
block	O
.	O

Additionally	O
,	O
E2F-1	B-protein
caused	O
massive	O
megakaryocyte	B-cell_type
accumulation	O
in	O
both	O
normal	O
and	O
ectopic	O
sites	O
,	O
first	O
evident	O
in	O
E15	O
embryonic	O
liver	O
.	O

Furthermore	O
,	O
significant	O
apoptosis	O
was	O
observed	O
in	O
transgenic	B-cell_type
megakaryocytes	I-cell_type
.	O

These	O
data	O
indicate	O
that	O
E2F-1	B-protein
can	O
prevent	O
terminal	O
differentiation	O
,	O
probably	O
through	O
its	O
cell	O
cycle-stimulatory	O
activity	O
.	O

MOLECULAR	NULL
AND	NULL
CELLULAR	NULL
BIOLOGY	NULL
,	NULL
Feb.	NULL
1996	NULL
,	NULL
p.	NULL
685-693	NULL
0270-7306/96/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1996	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

16	NULL
,	NULL
No	NULL
.	NULL

2	NULL
E2F-1	NULL
Blocks	NULL
Terminal	NULL
Differentiation	NULL
and	NULL
Causes	NULL
Proliferation	NULL
in	NULL
Transgenic	NULL
Megakaryocytes	NULL
CHANTALE	NULL
T.	NULL
GUY	NULL
,	NULL
WEN	NULL
ZHOU	NULL
,	NULL
STEPHEN	NULL
KAUFMAN	NULL
,	NULL
anp	NULL
MURRAY	NULL
O.	NULL
ROBINSON®	NULL
Amgen	NULL
,	NULL
Inc.	NULL
,	NULL
Thousand	NULL
Oaks	NULL
,	NULL
California	NULL
91320	NULL
Received	NULL
30	NULL
August	NULL
1995/Returned	NULL
for	NULL
modification	NULL
18	NULL
October	NULL
1995/Accepted	NULL
26	NULL
October	NULL
1995	NULL
The	NULL
transcription	NULL
factor	NULL
E2F-1	NULL
plays	NULL
a	NULL
central	NULL
role	NULL
in	NULL
the	NULL
cell	NULL
cycle	NULL
through	NULL
its	NULL
ability	NULL
to	NULL
activate	NULL
genes	NULL
involved	NULL
in	NULL
cell	NULL
division	NULL
.	NULL

E2F-1	NULL
activity	NULL
is	NULL
regulated	NULL
by	NULL
a	NULL
number	NULL
of	NULL
proteins	NULL
,	NULL
including	NULL
the	NULL
retinoblastoma	NULL
susceptibility	NULL
gene	NULL
product	NULL
,	NULL
cyclin-dependent	NULL
kinases	NULL
,	NULL
and	NULL
their	NULL
inhibitors	NULL
,	NULL
proteins	NULL
that	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
control	NULL
of	NULL
certain	NULL
developmental	NULL
processes	NULL
.	NULL

To	NULL
investigate	NULL
a	NULL
potential	NULL
role	NULL
of	NULL
E2F-1	NULL
in	NULL
differentiation	NULL
,	NULL
we	NULL
assayed	NULL
the	NULL
ability	NULL
of	NULL
megakaryocytes	NULL
to	NULL
form	NULL
platelets	NULL
in	NULL
an	NULL
in	NULL
vivo	NULL
transgenic	NULL
model	NULL
.	NULL

E2F-1	NULL
expression	NULL
in	NULL
megakaryocytes	NULL
blocked	NULL
differentiation	NULL
during	NULL
maturation	NULL
,	NULL
resulting	NULL
in	NULL
severe	NULL
thrombocytopenia	NULL
.	NULL

Ultrastructural	NULL
analysis	NULL
of	NULL
megakaryocytes	NULL
revealed	NULL
abnormal	NULL
development	NULL
characterized	NULL
by	NULL
hyperdemarcation	NULL
of	NULL
cytoplasmic	NULL
membranes	NULL
and	NULL
reduced	NULL
numbers	NULL
of	NULL
alpha	NULL
granules	NULL
.	NULL

Administration	NULL
of	NULL
megakaryocyte	NULL
growth	NULL
and	NULL
development	NULL
factor	NULL
or	NULL
interleukin	NULL
6	NULL
could	NULL
not	NULL
overcome	NULL
the	NULL
differentiation	NULL
block	NULL
.	NULL

Additionally	NULL
,	NULL
E2F-1	NULL
caused	NULL
massive	NULL
megakaryocyte	NULL
accumulation	NULL
in	NULL
both	NULL
normal	NULL
and	NULL
ectopic	NULL
sites	NULL
,	NULL
first	NULL
evident	NULL
in	NULL
E15	NULL
embryonic	NULL
liver	NULL
.	NULL

Furthermore	NULL
,	NULL
significant	NULL
apoptosis	NULL
was	NULL
observed	NULL
in	NULL
transgenic	NULL
megakaryocytes	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
E2F-1	NULL
can	NULL
prevent	NULL
terminal	NULL
differentiation	NULL
,	NULL
probably	NULL
through	NULL
its	NULL
cell	NULL
cycle-stimulatory	NULL
activity	NULL
.	NULL

E2F-1	NULL
is	NULL
a	NULL
transcription	NULL
factor	NULL
that	NULL
is	NULL
thought	NULL
to	NULL
play	NULL
a	NULL
central	NULL
role	NULL
in	NULL
the	NULL
control	NULL
of	NULL
cell	NULL
division	NULL
(	NULL
30	NULL
,	NULL
37	NULL
)	NULL
.	NULL

It	NULL
is	NULL
one	NULL
member	NULL
of	NULL
a	NULL
family	NULL
of	NULL
at	NULL
least	NULL
four	NULL
E2F	NULL
proteins	NULL
whose	NULL
functions	NULL
appear	NULL
to	NULL
be	NULL
similar	NULL
(	NULL
4	NULL
,	NULL
11	NULL
,	NULL
16	NULL
,	NULL
22	NULL
,	NULL
27	NULL
,	NULL
32	NULL
,	NULL
49	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
binding	NULL
and	NULL
transcriptional	NULL
activity	NULL
of	NULL
E2F-1	NULL
is	NULL
maximally	NULL
activated	NULL
by	NULL
heterodimerization	NULL
with	NULL
the	NULL
DP-1	NULL
family	NULL
of	NULL
proteins	NULL
(	NULL
2	NULL
,	NULL
12	NULL
,	NULL
17	NULL
,	NULL
28	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
active	NULL
complex	NULL
is	NULL
an	NULL
E2F-DP	NULL
heterodimer	NULL
.	NULL

E2F	NULL
binds	NULL
the	NULL
consensus	NULL
sequence	NULL
TTTCGCGC	NULL
and	NULL
activates	NULL
transcription	NULL
of	NULL
a	NULL
number	NULL
of	NULL
genes	NULL
involved	NULL
in	NULL
the	NULL
G	NULL
,	NULL
and	NULL
S	NULL
phases	NULL
of	NULL
cell	NULL
division	NULL
.	NULL

Such	NULL
genes	NULL
include	NULL
myc	NULL
(	NULL
35	NULL
)	NULL
,	NULL
myb	NULL
(	NULL
29	NULL
)	NULL
,	NULL
and	NULL
the	NULL
dihydrofolate	NULL
reductase	NULL
(	NULL
53	NULL
)	NULL
,	NULL
thymidine	NULL
kinase	NULL
(	NULL
7	NULL
)	NULL
,	NULL
thymidylate	NULL
synthetase	NULL
(	NULL
34	NULL
)	NULL
,	NULL
DNA	NULL
polymerase	NULL
«	NULL
and	NULL
cyclin	NULL
D1	NULL
(	NULL
45	NULL
)	NULL
,	NULL
and	NULL
E2F-1	NULL
(	NULL
20	NULL
,	NULL
25	NULL
,	NULL
36	NULL
)	NULL
genes	NULL
.	NULL

These	NULL
genes	NULL
contain	NULL
E2F	NULL
consensus	NULL
sites	NULL
in	NULL
their	NULL
promoters	NULL
and/or	NULL
are	NULL
transcriptionally	NULL
responsive	NULL
to	NULL
E2F	NULL
protein	NULL
.	NULL

The	NULL
expression	NULL
and	NULL
effects	NULL
of	NULL
E2F-1	NULL
in	NULL
cultured	NULL
cells	NULL
have	NULL
been	NULL
well	NULL
characterized	NULL
.	NULL

E2F-1	NULL
mRNA	NULL
is	NULL
cell	NULL
cycle	NULL
regulated	NULL
,	NULL
appearing	NULL
during	NULL
G/G	NULL
,	NULL
through	NULL
S	NULL
(	NULL
27	NULL
,	NULL
49	NULL
,	NULL
53	NULL
)	NULL
.	NULL

Overexpression	NULL
of	NULL
E2F-1	NULL
in	NULL
3T	NULL
3	NULL
cells	NULL
causes	NULL
reentry	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
26	NULL
,	NULL
58	NULL
)	NULL
and	NULL
,	NULL
in	NULL
primary	NULL
fibroblasts	NULL
,	NULL
causes	NULL
transformation	NULL
(	NULL
24	NULL
,	NULL
51	NULL
)	NULL
.	NULL

E2F-1	NULL
is	NULL
positively	NULL
correlated	NULL
with	NULL
cell	NULL
proliferation	NULL
,	NULL
as	NULL
E2F-1	NULL
is	NULL
expressed	NULL
in	NULL
all	NULL
tumor	NULL
cell	NULL
lines	NULL
assayed	NULL
(	NULL
16	NULL
,	NULL
32	NULL
)	NULL
and	NULL
is	NULL
undetectable	NULL
in	NULL
senescent	NULL
cells	NULL
in	NULL
culture	NULL
(	NULL
6	NULL
)	NULL
.	NULL

E2F	NULL
function	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
regulated	NULL
by	NULL
a	NULL
cascade	NULL
of	NULL
cell	NULL
cycle-regulatory	NULL
proteins	NULL
.	NULL

E2F-1	NULL
is	NULL
a	NULL
target	NULL
of	NULL
the	NULL
tumor	NULL
suppressor	NULL
Rb	NULL
,	NULL
the	NULL
product	NULL
of	NULL
the	NULL
retinoblastoma	NULL
susceptibility	NULL
gene	NULL
and	NULL
a	NULL
protein	NULL
with	NULL
an	NULL
inhibitory	NULL
effect	NULL
on	NULL
proliferation	NULL
.	NULL

E2F-1	NULL
interacts	NULL
directly	NULL
with	NULL
Rb	NULL
,	NULL
resulting	NULL
in	NULL
suppression	NULL
of	NULL
E2F-mediated	NULL
transactivation	NULL
(	NULL
9	NULL
,	NULL
15	NULL
)	NULL
.	NULL

Rb	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
is	NULL
negatively	NULL
regulated	NULL
through	NULL
phosphorylation	NULL
by	NULL
the	NULL
cyclin-dependent	NULL
kinases	NULL
(	NULL
CDKs	NULL
)	NULL
.	NULL

CDKs	NULL
are	NULL
themselves	NULL
inhibited	NULL
by	NULL
the	NULL
p16	NULL
and	NULL
p21	NULL
classes	NULL
of	NULL
kinase	NULL
inhibitors	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
E2F-1	NULL
can	NULL
induce	NULL
DNA	NULL
synthesis	NULL
in	NULL
transforming	NULL
growth	NULL
factor	NULL
B	NULL
growth-inhibited	NULL
mink	NULL
lung	NULL
epithelial	NULL
cells	NULL
(	NULL
47	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
E2F-1	NULL
acts	NULL
downstream	NULL
of	NULL
transforming	NULL
growth	NULL
factor	NULL
B	NULL
,	NULL
which	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
block	NULL
the	NULL
cell	NULL
cycle	NULL
through	NULL
one	NULL
or	NULL
more	NULL
of	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
805	NULL
)	NULL
447-4892	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
805	NULL
)	NULL
499-8129	NULL
.	NULL

685	NULL
the	NULL
CDK	NULL
inhibitors	NULL
.	NULL

Additionally	NULL
,	NULL
the	NULL
p16	NULL
CDK	NULL
inhibitor	NULL
can	NULL
block	NULL
EZF	NULL
activity	NULL
in	NULL
a	NULL
cyclin	NULL
D1-stimulated	NULL
cell	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Recent	NULL
data	NULL
suggest	NULL
that	NULL
Rb	NULL
,	NULL
cyclin	NULL
D1	NULL
,	NULL
and	NULL
p21	NULL
may	NULL
play	NULL
a	NULL
significant	NULL
role	NULL
in	NULL
differentiation	NULL
of	NULL
muscle	NULL
.	NULL

Rb	NULL
appears	NULL
to	NULL
be	NULL
necessary	NULL
for	NULL
proper	NULL
differentiation	NULL
of	NULL
cultured	NULL
myoblasts	NULL
(	NULL
13	NULL
)	NULL
,	NULL
cyclin	NULL
D1	NULL
can	NULL
inhibit	NULL
myogenic	NULL
differentiation	NULL
,	NULL
an	NULL
effect	NULL
counteracted	NULL
by	NULL
coexpression	NULL
of	NULL
p16	NULL
or	NULL
p21	NULL
(	NULL
52	NULL
)	NULL
,	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
p21	NULL
CDK	NULL
inhibitor	NULL
is	NULL
positively	NULL
correlated	NULL
with	NULL
muscle	NULL
differentiation	NULL
(	NULL
14	NULL
,	NULL
40	NULL
)	NULL
.	NULL

Functional	NULL
inactivation	NULL
of	NULL
the	NULL
Rb	NULL
gene	NULL
in	NULL
mice	NULL
results	NULL
in	NULL
developmental	NULL
defects	NULL
in	NULL
erythrocytes	NULL
and	NULL
some	NULL
neurons	NULL
(	NULL
5	NULL
,	NULL
23	NULL
,	NULL
31	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
postulated	NULL
that	NULL
Rb	NULL
acts	NULL
by	NULL
causing	NULL
cells	NULL
to	NULL
exit	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
56	NULL
)	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
Rb	NULL
and	NULL
p21	NULL
accomplish	NULL
this	NULL
through	NULL
their	NULL
ability	NULL
to	NULL
directly	NULL
or	NULL
indirectly	NULL
inhibit	NULL
EZF	NULL
,	NULL
suggesting	NULL
that	NULL
E2F	NULL
may	NULL
act	NULL
to	NULL
prevent	NULL
differentiation	NULL
.	NULL

EZ2F-1	NULL
is	NULL
present	NULL
in	NULL
a	NULL
number	NULL
of	NULL
human	NULL
tissue	NULL
RNAs	NULL
(	NULL
27	NULL
)	NULL
,	NULL
including	NULL
,	NULL
paradoxically	NULL
,	NULL
RNAs	NULL
of	NULL
tissues	NULL
usually	NULL
associated	NULL
with	NULL
very	NULL
little	NULL
mitotic	NULL
activity	NULL
.	NULL

The	NULL
function	NULL
or	NULL
regulation	NULL
of	NULL
E2F	NULL
in	NULL
cells	NULL
in	NULL
vivo	NULL
is	NULL
not	NULL
well	NULL
un-derstood	NULL
.	NULL

To	NULL
address	NULL
the	NULL
role	NULL
of	NULL
E2F-1	NULL
in	NULL
differentiation	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
consequences	NULL
of	NULL
deregulation	NULL
of	NULL
E2F-1	NULL
expression	NULL
in	NULL
vivo	NULL
by	NULL
using	NULL
the	NULL
well-defined	NULL
differentiative	NULL
process	NULL
of	NULL
platelet	NULL
formation	NULL
as	NULL
a	NULL
model	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
10	NULL
)	NULL
.	NULL

Megakaryocyte	NULL
precursors	NULL
proliferate	NULL
and	NULL
then	NULL
exit	NULL
the	NULL
cell	NULL
cycle	NULL
as	NULL
dip-loid	NULL
megakaryoblasts	NULL
.	NULL

These	NULL
cells	NULL
,	NULL
readily	NULL
identifiable	NULL
because	NULL
of	NULL
their	NULL
large	NULL
size	NULL
,	NULL
mature	NULL
through	NULL
three	NULL
morphologically	NULL
defined	NULL
stages	NULL
,	NULL
finally	NULL
fragmenting	NULL
into	NULL
blood	NULL
platelets	NULL
.	NULL

Experimental	NULL
manipulation	NULL
of	NULL
this	NULL
process	NULL
can	NULL
be	NULL
easily	NULL
assayed	NULL
by	NULL
monitoring	NULL
circulating	NULL
platelet	NULL
levels	NULL
in	NULL
peripheral	NULL
blood	NULL
.	NULL

Furthermore	NULL
,	NULL
megakaryocyte	NULL
proliferation	NULL
and	NULL
differentiation	NULL
can	NULL
be	NULL
positively	NULL
regulated	NULL
by	NULL
several	NULL
factors	NULL
,	NULL
including	NULL
the	NULL
recently	NULL
cloned	NULL
megakaryocyte	NULL
growth	NULL
and	NULL
development	NULL
factor	NULL
(	NULL
MGDF	NULL
)	NULL
(	NULL
3	NULL
,	NULL
33	NULL
)	NULL
.	NULL

To	NULL
target	NULL
E2F-1	NULL
expression	NULL
to	NULL
megakaryocytes	NULL
,	NULL
we	NULL
generated	NULL
transgenic	NULL
mice	NULL
expressing	NULL
the	NULL
human	NULL
E2F-1	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
megakaryocyte-specific	NULL
platelet	NULL
factor	NULL
4	NULL
(	NULL
PF4	NULL
)	NULL
promoter	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
this	NULL
promoter	NULL
is	NULL
thought	NULL
to	NULL
initiate	NULL
as	NULL
the	NULL
megakaryocytes	NULL
exit	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
such	NULL
that	NULL
effects	NULL
of	NULL
the	NULL
transgene	NULL
would	NULL
be	NULL
primarily	NULL
directed	NULL
to	NULL
postmitotic	NULL
megakaryocytes	NULL
.	NULL

686	NULL
GUY	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
50	NULL
ng	NULL
100	NULL
ng	NULL
200	NULL
ng	NULL
INv—ON	NULL
w	NULL
-	NULL
o	NULL
o	NULL
w	NULL
-	NULL
o	NULL
a	NULL
gpsgi	NULL
a	NULL
n	NULL
ano	NULL
3	NULL
arno	NULL
aa	NULL
2	NULL
a	NULL
a	NULL
nor	NULL
2	NULL
huE2F-1	NULL
®	NULL
me	NULL
ai	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

FIG	NULL
.	NULL

1	NULL
.	NULL

Expression	NULL
of	NULL
human	NULL
E2F-1	NULL
in	NULL
transgenic	NULL
megakaryocytes	NULL
.	NULL

(	NULL
A	NULL
)	NULL
RT-PCR	NULL
analysis	NULL
of	NULL
huE2F-1	NULL
expression	NULL
in	NULL
transgenic	NULL
bone	NULL
marrow	NULL
RNA	NULL
.	NULL

Fifty	NULL
,	NULL
100	NULL
,	NULL
or	NULL
200	NULL
ng	NULL
of	NULL
total	NULL
RNA	NULL
from	NULL
bone	NULL
marrow	NULL
of	NULL
the	NULL
indicated	NULL
transgenic	NULL
(	NULL
PE	NULL
series	NULL
)	NULL
or	NULL
wild-type	NULL
(	NULL
w.t	NULL
.	NULL
)	NULL

mice	NULL
was	NULL
reverse	NULL
transcribed	NULL
,	NULL
amplified	NULL
for	NULL
25	NULL
cycles	NULL
,	NULL
and	NULL
analyzed	NULL
.	NULL

The	NULL
amplified	NULL
products	NULL
for	NULL
huE2F-1	NULL
and	NULL
GAPDH	NULL
were	NULL
321	NULL
and	NULL
352	NULL
bp	NULL
long	NULL
,	NULL
respectively	NULL
.	NULL

Exposure	NULL
times	NULL
were	NULL
72	NULL
h	NULL
for	NULL
E2F-1	NULL
and	NULL
1	NULL
h	NULL
for	NULL
GAPDH	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Immunostaining	NULL
of	NULL
huE2F-1	NULL
protein	NULL
in	NULL
megakaryocytes	NULL
.	NULL

Shown	NULL
is	NULL
two-color	NULL
immunostaining	NULL
of	NULL
the	NULL
indicated	NULL
bone	NULL
marrow	NULL
sections	NULL
,	NULL
using	NULL
antibodies	NULL
directed	NULL
against	NULL
either	NULL
E2F-1	NULL
protein	NULL
(	NULL
red	NULL
)	NULL
or	NULL
megakaryocyte	NULL
marker	NULL
PF4	NULL
(	NULL
green	NULL
)	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
imaged	NULL
on	NULL
an	NULL
ACAS	NULL
confocal	NULL
microscope	NULL
and	NULL
processed	NULL
by	NULL
using	NULL
Adobe	NULL
Photoshop	NULL
3.0	NULL
.	NULL

Magnification	NULL
,	NULL
X62	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Transgenic	NULL
mice	NULL
.	NULL

A	NULL
1.2-kb	NULL
EcoRV-BamHI	NULL
fragment	NULL
of	NULL
the	NULL
human	NULL
E2F-1	NULL
(	NULL
buE2F-1	NULL
)	NULL
cDNA	NULL
was	NULL
filled	NULL
in	NULL
with	NULL
Klenow	NULL
enzyme	NULL
and	NULL
cloned	NULL
into	NULL
the	NULL
EcoRV	NULL
site	NULL
of	NULL
an	NULL
expression	NULL
cassette	NULL
containing	NULL
1.1	NULL
kb	NULL
of	NULL
the	NULL
rat	NULL
PF4	NULL
upstream	NULL
region	NULL
5	NULL
'	NULL
to	NULL
the	NULL
EcoRV	NULL
site	NULL
followed	NULL
3	NULL
'	NULL
by	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
small-T	NULL
intron	NULL
and	NULL
poly-adenylation	NULL
sequences	NULL
.	NULL

The	NULL
construct	NULL
was	NULL
isolated	NULL
as	NULL
a	NULL
NofI-Xhol	NULL
fragment	NULL
,	NULL
and	NULL
transgenic	NULL
mice	NULL
were	NULL
generated	NULL
by	NULL
pronuclear	NULL
injection	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Transgenic	NULL
lines	NULL
were	NULL
screened	NULL
by	NULL
using	NULL
PCR	NULL
with	NULL
oligonucleotide	NULL
primers	NULL
used	NULL
for	NULL
the	NULL
reverse	NULL
transcription	NULL
(	NULL
RT	NULL
)	NULL
-PCR	NULL
analysis	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

Homozygous	NULL
mice	NULL
were	NULL
identified	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Histology	NULL
.	NULL

Tissues	NULL
from	NULL
adults	NULL
(	NULL
4	NULL
weeks	NULL
old	NULL
)	NULL
and	NULL
fetuses	NULL
(	NULL
day	NULL
15	NULL
postcoitus	NULL
)	NULL
were	NULL
harvested	NULL
from	NULL
normal	NULL
and	NULL
transgenic	NULL
animals	NULL
,	NULL
fixed	NULL
in	NULL
10	NULL
%	NULL
zinc-formalin	NULL
,	NULL
and	NULL
embedded	NULL
in	NULL
paraffin	NULL
.	NULL

Femurs	NULL
were	NULL
additionally	NULL
decalcified	NULL
(	NULL
J.	NULL
T.	NULL
Baker	NULL
)	NULL
for	NULL
1	NULL
h	NULL
following	NULL
fixation	NULL
.	NULL

Tissues	NULL
were	NULL
cut	NULL
into	NULL
4-wm	NULL
sections	NULL
and	NULL
stained	NULL
with	NULL
hematoxylin	NULL
and	NULL
eosin	NULL
(	NULL
Fischer	NULL
)	NULL
for	NULL
examination	NULL
.	NULL

Megakaryocyte	NULL
numbers	NULL
were	NULL
determined	NULL
by	NULL
photographing	NULL
the	NULL
bone	NULL
marrow	NULL
and	NULL
spleen	NULL
sections	NULL
at	NULL
magnifications	NULL
of	NULL
X400	NULL
and	NULL
X100	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
then	NULL
counting	NULL
megakaryocytes	NULL
in	NULL
the	NULL
photograph	NULL
and	NULL
determining	NULL
the	NULL
size	NULL
of	NULL
the	NULL
photographic	NULL
field	NULL
.	NULL

Data	NULL
are	NULL
presented	NULL
as	NULL
cells	NULL
per	NULL
0.5-mm	NULL
>	NULL
area	NULL
.	NULL

Detection	NULL
of	NULL
apoptotic	NULL
cells	NULL
.	NULL

Apoptotic	NULL
cells	NULL
were	NULL
detected	NULL
by	NULL
using	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
terminal	NULL
deoxynucleotidyl	NULL
transferase-mediated	NULL
dUTP-biotin	NULL
nick	NULL
end-labeling	NULL
(	NULL
TUNEL	NULL
)	NULL
method	NULL
by	NULL
amplifying	NULL
the	NULL
apoptotic	NULL
signal	NULL
with	NULL
a	NULL
three-step	NULL
staining	NULL
procedure	NULL
(	NULL
54	NULL
)	NULL
.	NULL

Spleen	NULL
sections	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
above	NULL
,	NULL
and	NULL
then	NULL
endogenous	NULL
peroxidase	NULL
activity	NULL
was	NULL
quenched	NULL
with	NULL
a	NULL
solution	NULL
of	NULL
0.1	NULL
%	NULL
of	NULL
phenylhydrazine	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
.	NULL

Peripheral	NULL
blood	NULL
analysis	NULL
.	NULL

One	NULL
hundred	NULL
microliters	NULL
of	NULL
blood	NULL
from	NULL
the	NULL
lateral	NULL
tail	NULL
vein	NULL
was	NULL
mixed	NULL
with	NULL
1/10	NULL
volume	NULL
of	NULL
3	NULL
%	NULL
EDTA	NULL
and	NULL
examined	NULL
on	NULL
a	NULL
Technicon	NULL
H1-E	NULL
hematology	NULL
analyzer	NULL
(	NULL
Myles	NULL
,	NULL
Tarrytown	NULL
,	NULL
N.Y.	NULL
)	NULL
.	NULL

Blood	NULL
smears	NULL
were	NULL
prepared	NULL
by	NULL
spreading	NULL
peripheral	NULL
blood	NULL
onto	NULL
a	NULL
glass	NULL
slide	NULL
and	NULL
staining	NULL
for	NULL
1	NULL
min	NULL
with	NULL
a	NULL
differential	NULL
polychrome	NULL
stain	NULL
(	NULL
Fischer	NULL
)	NULL
.	NULL

To	NULL
type	NULL
megakaryocytes	NULL
,	NULL
bone	NULL
marrow	NULL
from	NULL
three	NULL
animals	NULL
of	NULL
each	NULL
group	NULL
was	NULL
extruded	NULL
by	NULL
gentle	NULL
pneumatic	NULL
pressure	NULL
from	NULL
femurs	NULL
with	NULL
the	NULL
ends	NULL
removed	NULL
.	NULL

The	NULL
marrow	NULL
was	NULL
then	NULL
smeared	NULL
onto	NULL
glass	NULL
slides	NULL
and	NULL
stained	NULL
by	NULL
using	NULL
an	NULL
acrospray	NULL
hematology	NULL
slide	NULL
stainer	NULL
(	NULL
model	NULL
7120	NULL
;	NULL
Wescor	NULL
,	NULL
Inc.	NULL
,	NULL
Logan	NULL
,	NULL
Utah	NULL
)	NULL
.	NULL

The	NULL
megakaryocytes	NULL
were	NULL
identified	NULL
and	NULL
staged	NULL
according	NULL
to	NULL
previously	NULL
established	NULL
criteria	NULL
(	NULL
39	NULL
)	NULL
.	NULL

At	NULL
least	NULL
135	NULL
identifiable	NULL
cells	NULL
were	NULL
counted	NULL
for	NULL
cach	NULL
mouse	NULL
.	NULL

RT-PCR	NULL
analysis	NULL
.	NULL

For	NULL
the	NULL
RT-PCR	NULL
,	NULL
50	NULL
,	NULL
100	NULL
,	NULL
or	NULL
200	NULL
ng	NULL
of	NULL
total	NULL
RNA	NULL
from	NULL
bone	NULL
marrow	NULL
of	NULL
the	NULL
indicated	NULL
transgenic	NULL
(	NULL
PE	NULL
series	NULL
)	NULL
or	NULL
wild-type	NULL
mice	NULL
was	NULL
reverse	NULL
transcribed	NULL
,	NULL
amplified	NULL
for	NULL
25	NULL
cycles	NULL
by	NULL
using	NULL
huER2F-1	NULL
primers	NULL
,	NULL
and	NULL
analyzed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
43	NULL
)	NULL
except	NULL
that	NULL
recombinant	NULL
TH	NULL
polymerase	NULL
(	NULL
Per-kin	NULL
Elmer	NULL
,	NULL
Norwalk	NULL
,	NULL
Conn.	NULL
)	NULL
was	NULL
substituted	NULL
for	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
reverse	NULL
transcriptase	NULL
and	NULL
Taq	NULL
polymerase	NULL
.	NULL

Reactions	NULL
using	NULL
glyceraldehyde	NULL
phosphate	NULL
dehydrogenase	NULL
(	NULL
GAPDH	NULL
)	NULL
primers	NULL
were	NULL
included	NULL
to	NULL
demonstrate	NULL
uniformity	NULL
of	NULL
RNA	NULL
amount	NULL
and	NULL
efficiency	NULL
of	NULL
amplification	NULL
among	NULL
samples	NULL
.	NULL

Oligonucleotide	NULL
primers	NULL
used	NULL
for	NULL
RT-PCR	NULL
were	NULL
huE2F-1	NULL
(	NULL
forward	NULL
,	NULL
5-ACCTTCGTA	NULL
GCATTGCAGACC-3	NULL
'	NULL
;	NULL
reverse	NULL
,	NULL
5-TTCITTGCTCCAGGCTGAGTAG-3	NULL
'	NULL
)	NULL
and	NULL
GAPDH	NULL
(	NULL
forward	NULL
,	NULL
5-GGGTGGAGCCAAACGGGTCATC-3	NULL
'	NULL
;	NULL
reverse	NULL
,	NULL
GCCA	NULL
GTGAGCTTCCCGTTCAGC-3	NULL
'	NULL
)	NULL
.	NULL

Exposure	NULL
times	NULL
were	NULL
72	NULL
h	NULL
for	NULL
E2F-1	NULL
and	NULL
1	NULL
h	NULL
for	NULL
GAPDH	NULL
.	NULL

Quantitation	NULL
of	NULL
the	NULL
amount	NULL
of	NULL
radioactivity	NULL
in	NULL
each	NULL
band	NULL
was	NULL
performed	NULL
with	NULL
a	NULL
PhosphorImager	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
,	NULL
Sunnyvale	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Immunohistochemistry	NULL
.	NULL

Four-micrometer	NULL
sections	NULL
of	NULL
paraffin-embedded	NULL
for-malin-fixed	NULL
bone	NULL
marrow	NULL
samples	NULL
were	NULL
incubated	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
a	NULL
huE2F-1	NULL
mouse	NULL
monoclonal	NULL
antibody	NULL
(	NULL
KH95	NULL
;	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
Calif.	NULL
)	NULL
per	NULL
ml	NULL
and	NULL
polyclonal	NULL
rabbit	NULL
serum	NULL
specific	NULL
for	NULL
PF4	NULL
(	NULL
1:500	NULL
dilution	NULL
;	NULL
Alexis	NULL
Corp.	NULL
,	NULL
Switzerland	NULL
)	NULL
and	NULL
then	NULL
visualized	NULL
by	NULL
using	NULL
species-specific	NULL
secondary	NULL
antibodies	NULL
(	NULL
anti-mouse	NULL
antibody	NULL
conjugated	NULL
to	NULL
phycoerythrin	NULL
and	NULL
anti-rabbit	NULL
antibody	NULL
conjugated	NULL
to	NULL
fluorescein	NULL
isothiocyanate	NULL
;	NULL
1:200	NULL
dilution	NULL
;	NULL
Dako	NULL
,	NULL
Carpin-teria	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

The	NULL
slides	NULL
were	NULL
imaged	NULL
on	NULL
an	NULL
ACAS	NULL
confocal	NULL
microscope	NULL
(	NULL
Merid-ian	NULL
Instruments	NULL
,	NULL
Okemus	NULL
,	NULL
Mich.	NULL
)	NULL
and	NULL
processed	NULL
by	NULL
using	NULL
Adobe	NULL
Photoshop	NULL
version	NULL
3.0	NULL
(	NULL
Adobe	NULL
Systems	NULL
,	NULL
Inc.	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Electron	NULL
microscopy	NULL
.	NULL

Femurs	NULL
from	NULL
control	NULL
and	NULL
transgenic	NULL
mice	NULL
were	NULL
excised	NULL
,	NULL
split	NULL
lengthwise	NULL
,	NULL
and	NULL
immersed	NULL
in	NULL
2.0	NULL
%	NULL
glutaraldehyde	NULL
in	NULL
0.1	NULL
M	NULL
sodium	NULL
cacody-late	NULL
buffer	NULL
at	NULL
pH	NULL
7.3	NULL
.	NULL

After	NULL
overnight	NULL
fixation	NULL
,	NULL
the	NULL
marrow	NULL
was	NULL
gently	NULL
extracted	NULL
and	NULL
rinsed	NULL
in	NULL
buffer	NULL
for	NULL
24	NULL
h.	NULL
The	NULL
tissue	NULL
was	NULL
postfixed	NULL
in	NULL
1	NULL
%	NULL
aqueous	NULL
osmium	NULL
tetroxide	NULL
prior	NULL
to	NULL
alcoholic	NULL
dehydration	NULL
and	NULL
infiltration	NULL
with	NULL
Medcast	NULL
epoxy	NULL
resin	NULL
(	NULL
Ted	NULL
Pella	NULL
,	NULL
Redding	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Following	NULL
polymerization	NULL
,	NULL
sections	NULL
were	NULL
cut	NULL
from	NULL
each	NULL
block	NULL
and	NULL
stained	NULL
with	NULL
toluidine	NULL
blue	NULL
.	NULL

Selected	NULL
areas	NULL
were	NULL
ultrathin	NULL
sectioned	NULL
.	NULL

The	NULL
sections	NULL
were	NULL
contrast	NULL
enhanced	NULL
with	NULL
uranyl	NULL
acetate	NULL
and	NULL
lead	NULL
citrate	NULL
prior	NULL
to	NULL
examination	NULL
on	NULL
a	NULL
Philips	NULL
CM120	NULL
transmission	NULL
electron	NULL
microscope	NULL
.	NULL

RESULTS	NULL
Generation	NULL
of	NULL
E2F-1	NULL
transgenic	NULL
mice	NULL
.	NULL

Following	NULL
microinjec-tion	NULL
,	NULL
several	NULL
lines	NULL
of	NULL
mice	NULL
were	NULL
established	NULL
,	NULL
and	NULL
four	NULL
of	NULL
these	NULL
were	NULL
assayed	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
huEZ2F-1	NULL
mRNA	NULL
in	NULL
bone	NULL
marrow	NULL
by	NULL
semiquantitative	NULL
RT-PCR	NULL
using	NULL
huE2F-1	NULL
primers	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Primers	NULL
were	NULL
chosen	NULL
such	NULL
that	NULL
mouse	NULL
E2F-1	NULL
sequences	NULL
would	NULL
not	NULL
be	NULL
amplified	NULL
.	NULL

All	NULL
four	NULL
transgenic	NULL
lines	NULL
expressed	NULL
the	NULL
transgene	NULL
,	NULL
albeit	NULL
at	NULL
different	NULL
levels	NULL
.	NULL

Bone	NULL
marrow	NULL
RNA	NULL
from	NULL
line	NULL
PE82	NULL
appeared	NULL
to	NULL
have	NULL
the	NULL
highest	NULL
levels	NULL
of	NULL
expression	NULL
,	NULL
followed	NULL
by	NULL
PES1	NULL
>	NULL
PE50	NULL
>	NULL
PE4Z	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

Nontransgenic	NULL
mice	NULL
did	NULL
not	NULL
show	NULL
any	NULL
amplification	NULL
of	NULL
huE2F-1	NULL
sequences	NULL
.	NULL

Quantitation	NULL
of	NULL
the	NULL
DNA	NULL
in	NULL
each	NULL
band	NULL
with	NULL
a	NULL
Molecular	NULL
Dynamics	NULL
PhosphorImager	NULL
showed	NULL
a	NULL
10-fold	NULL
range	NULL
of	NULL
expression	NULL
between	NULL
the	NULL
highest-	NULL
and	NULL
lowest-expressing	NULL
lines	NULL
.	NULL

To	NULL
determine	NULL
which	NULL
cells	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
were	NULL
expressing	NULL
huE2F-1	NULL
protein	NULL
,	NULL
double	NULL
immunostaining	NULL
and	NULL
confocal	NULL
microscopic	NULL
imaging	NULL
were	NULL
performed	NULL
on	NULL
bone	NULL
marrow	NULL
sections	NULL
from	NULL
the	NULL
PE82	NULL
line	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Use	NULL
of	NULL
anti-E2F-1	NULL
antibodies	NULL
and	NULL
a	NULL
phycoerythrin-labeled	NULL
secondary	NULL
antibody	NULL
revealed	NULL
nuclear	NULL
staining	NULL
in	NULL
transgenic	NULL
megakaryocytes	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
no	NULL
staining	NULL
was	NULL
observed	NULL
in	NULL
megakaryocytes	NULL
from	NULL
nontransgenic	NULL
bone	NULL
marrow	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Although	NULL
megakaryocytes	NULL
can	NULL
be	NULL
identified	NULL
by	NULL
their	NULL
large	NULL
size	NULL
and	NULL
distinct	NULL
morphology	NULL
,	NULL
immunostaining	NULL
with	NULL
antibodies	NULL
against	NULL
PF4	NULL
,	NULL
a	NULL
cytoplasmic	NULL
megakaryocyte-specific	NULL
marker	NULL
whose	NULL
promoter	NULL
drives	NULL
E2F-1	NULL
expression	NULL
,	NULL
was	NULL
used	NULL
to	NULL
confirm	NULL
the	NULL
identification	NULL
of	NULL
both	NULL
transgenic	NULL
and	NULL
nontransgenic	NULL
megakaryocytes	NULL
.	NULL

Green	NULL
cytoplasmic	NULL
fluorescence	NULL
confirmed	NULL
the	NULL
identity	NULL
of	NULL
the	NULL
megakaryocytes	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
EZ2F-1	NULL
BLOCKS	NULL
TERMINAL	NULL
DIFFERENTIATION	NULL
687	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Differentiation	NULL
block	NULL
in	NULL
E2F-1	NULL
transgenic	NULL
mice	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Thrombocytopenia	NULL
in	NULL
E2F-l-expressing	NULL
mice	NULL
.	NULL

Platelet	NULL
counts	NULL
from	NULL
several	NULL
mice	NULL
(	NULL
#	NULL
>	NULL
11	NULL
)	NULL
of	NULL
each	NULL
indicated	NULL
transgenic	NULL
and	NULL
normal	NULL
line	NULL
were	NULL
determined	NULL
.	NULL

The	NULL
data	NULL
are	NULL
presented	NULL
as	NULL
means	NULL
+	NULL
SDs	NULL
of	NULL
individual	NULL
determinations	NULL
.	NULL

The	NULL
P	NULL
value	NULL
was	NULL
<	NULL
0.01	NULL
for	NULL
the	NULL
difference	NULL
between	NULL
the	NULL
platelet	NULL
counts	NULL
of	NULL
PES5O	NULL
**	NULL
and	NULL
PE50*'~	NULL
mice	NULL
.	NULL

w.t	NULL
.	NULL

,	NULL
wild	NULL
type	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Absence	NULL
of	NULL
platelets	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
E2F-1-expressing	NULL
mice	NULL
.	NULL

Representative	NULL
platelets	NULL
are	NULL
indicated	NULL
by	NULL
arrowheads	NULL
.	NULL

Note	NULL
the	NULL
absence	NULL
of	NULL
platelets	NULL
in	NULL
the	NULL
blood	NULL
of	NULL
the	NULL
transgenic	NULL
animal	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
a	NULL
normal	NULL
littermate	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Maturation	NULL
block	NULL
in	NULL
megakaryocytes	NULL
expressing	NULL
E2F-1	NULL
.	NULL

The	NULL
data	NULL
are	NULL
presented	NULL
as	NULL
mean	NULL
percentages	NULL
+	NULL
SDs	NULL
.	NULL

E2F-1	NULL
blocks	NULL
terminal	NULL
differentiation	NULL
of	NULL
megakaryocytes	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
possible	NULL
effects	NULL
of	NULL
E2F-1	NULL
expression	NULL
in	NULL
megakaryocytes	NULL
,	NULL
blood	NULL
samples	NULL
from	NULL
several	NULL
mice	NULL
of	NULL
each	NULL
line	NULL
were	NULL
analyzed	NULL
by	NULL
blood	NULL
smears	NULL
and	NULL
by	NULL
a	NULL
Technicon	NULL
H-1E	NULL
hematology	NULL
analyzer	NULL
for	NULL
alterations	NULL
in	NULL
peripheral	NULL
blood	NULL
parameters	NULL
.	NULL

The	NULL
highest-expressing	NULL
line	NULL
,	NULL
PE82	NULL
,	NULL
exhibited	NULL
severe	NULL
thrombocyto-penia	NULL
,	NULL
with	NULL
platelet	NULL
levels	NULL
measured	NULL
at	NULL
87	NULL
X	NULL
10°/pul	NULL
of	NULL
blood	NULL
(	NULL
standard	NULL
deviation	NULL
[	NULL
SD	NULL
]	NULL
,	NULL
21	NULL
%	NULL
10°/pl	NULL
of	NULL
blood	NULL
)	NULL
,	NULL
representing	NULL
only	NULL
7	NULL
%	NULL
of	NULL
normal	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

This	NULL
value	NULL
is	NULL
likely	NULL
an	NULL
overestimate	NULL
of	NULL
the	NULL
actual	NULL
platelet	NULL
count	NULL
as	NULL
a	NULL
result	NULL
of	NULL
contamination	NULL
of	NULL
the	NULL
platelet	NULL
window	NULL
with	NULL
other	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
support	NULL
of	NULL
this	NULL
assertion	NULL
,	NULL
no	NULL
blood	NULL
platelets	NULL
could	NULL
be	NULL
detected	NULL
by	NULL
cytologic	NULL
examination	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

The	NULL
other	NULL
three	NULL
lines	NULL
exhibited	NULL
lesser	NULL
degrees	NULL
of	NULL
thrombocytopenia	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
;	NULL
platelet	NULL
numbers	NULL
given	NULL
by	NULL
the	NULL
H-1E	NULL
analyzer	NULL
were	NULL
consistent	NULL
with	NULL
the	NULL
platelet	NULL
levels	NULL
observed	NULL
in	NULL
blood	NULL
smears	NULL
of	NULL
each	NULL
line	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

All	NULL
other	NULL
hematopoietic	NULL
cell	NULL
values	NULL
assayed	NULL
were	NULL
within	NULL
the	NULL
range	NULL
of	NULL
the	NULL
negative	NULL
littermates	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Each	NULL
line	NULL
maintained	NULL
a	NULL
specific	NULL
level	NULL
of	NULL
thrombo-cytopenia	NULL
,	NULL
the	NULL
severity	NULL
of	NULL
which	NULL
correlated	NULL
directly	NULL
with	NULL
the	NULL
level	NULL
of	NULL
E2F-1	NULL
mRNA	NULL
.	NULL

Homozygous	NULL
mice	NULL
generated	NULL
from	NULL
line	NULL
PE50	NULL
confirmed	NULL
this	NULL
correlation	NULL
,	NULL
as	NULL
mice	NULL
carrying	NULL
two	NULL
insertions	NULL
of	NULL
the	NULL
transgene	NULL
had	NULL
lower	NULL
platelet	NULL
counts	NULL
than	NULL
their	NULL
heterozygote	NULL
littermates	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

This	NULL
relationship	NULL
between	NULL
expression	NULL
level	NULL
and	NULL
degree	NULL
of	NULL
thrombocytopenia	NULL
suggests	NULL
that	NULL
the	NULL
transgene	NULL
exerts	NULL
its	NULL
effects	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
defect	NULL
present	NULL
in	NULL
these	NULL
mice	NULL
,	NULL
megakaryocytes	NULL
in	NULL
the	NULL
PE82	NULL
bone	NULL
marrow	NULL
were	NULL
further	NULL
analyzed	NULL
.	NULL

The	NULL
cells	NULL
appeared	NULL
larger	NULL
than	NULL
normal	NULL
and	NULL
displayed	NULL
unusually	NULL
large	NULL
nuclei	NULL
,	NULL
some	NULL
nuclei	NULL
appearing	NULL
as	NULL
ring	NULL
struc-tures	NULL
.	NULL

Despite	NULL
the	NULL
unusual	NULL
appearance	NULL
of	NULL
the	NULL
megakaryocytes	NULL
,	NULL
it	NULL
was	NULL
possible	NULL
to	NULL
determine	NULL
their	NULL
maturation	NULL
stage	NULL
by	NULL
using	NULL
standard	NULL
criteria	NULL
(	NULL
39	NULL
)	NULL
.	NULL

The	NULL
majority	NULL
(	NULL
54	NULL
%	NULL
)	NULL
of	NULL
the	NULL
megakaryocytes	NULL
evaluated	NULL
in	NULL
the	NULL
transgenic	NULL
bone	NULL
marrow	NULL
were	NULL
morphologically	NULL
judged	NULL
to	NULL
be	NULL
stage	NULL
2	NULL
,	NULL
characterized	NULL
by	NULL
a	NULL
lobated	NULL
nu-cleus	NULL
,	NULL
a	NULL
lightly	NULL
basophilic	NULL
cytoplasm	NULL
,	NULL
and	NULL
lack	NULL
of	NULL
granulation	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

Normal	NULL
control	NULL
mice	NULL
had	NULL
equal	NULL
numbers	NULL
of	NULL
the	NULL
three	NULL
stages	NULL
.	NULL

Ultrastructural	NULL
analysis	NULL
of	NULL
bone	NULL
marrow	NULL
megakaryocytes	NULL
from	NULL
the	NULL
PE82	NULL
line	NULL
demonstrated	NULL
further	NULL
evidence	NULL
of	NULL
abnormal	NULL
differentiation	NULL
.	NULL

Nontransgenic	NULL
megakaryocytes	NULL
exhibited	NULL
typical	NULL
networks	NULL
of	NULL
cytoplasmic	NULL
membrane	NULL
formation	NULL
that	NULL
define	NULL
and	NULL
demarcate	NULL
the	NULL
presumptive	NULL
nascent	NULL
platelets	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
cytoplasm	NULL
of	NULL
the	NULL
transgenic	NULL
megakaryocytes	NULL
displayed	NULL
regions	NULL
of	NULL
hyperdemarcation	NULL
,	NULL
often	NULL
excluding	NULL
alpha	NULL
granules	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

The	NULL
numbers	NULL
of	NULL
alpha	NULL
688	NULL
GUY	NULL
ET	NULL
AL	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

FIG	NULL
.	NULL

3	NULL
.	NULL

Ultrastructural	NULL
defects	NULL
in	NULL
PES2	NULL
megakaryocytes	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Wild-type	NULL
megakaryocyte	NULL
showing	NULL
typic	NULL
dense	NULL
alpha	NULL
granules	NULL
(	NULL
arrowheads	NULL
)	NULL
.	NULL

This	NULL
regular	NULL
pattern	NULL
defines	NULL
presumptive	NULL
regions	NULL
of	NULL
nascent	NULL
platelet	NULL
formation	NULL
.	NULL

Nu	NULL
,	NULL
nucleus	NULL
.	NULL

(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
Typical	NULL
PE82	NULL
megakaryocytes	NULL
.	NULL

Note	NULL
the	NULL
relative	NULL
paucity	NULL
of	NULL
the	NULL
alpha	NULL
granules	NULL
and	NULL
the	NULL
regions	NULL
of	NULL
abnormal	NULL
demarcation	NULL
membrane	NULL
formation	NULL
(	NULL
asterisks	NULL
)	NULL
.	NULL

Disorganized	NULL
demarcation	NULL
membranes	NULL
do	NULL
not	NULL
appear	NULL
to	NULL
form	NULL
regions	NULL
of	NULL
nascent	NULL
platelet	NULL
formation	NULL
.	NULL

(	NULL
D	NULL
)	NULL
PES2	NULL
endomitosis	NULL
.	NULL

Occasional	NULL
nuclei	NULL
from	NULL
PE82	NULL
megakaryocytes	NULL
display	NULL
chromatin	NULL
(	NULL
Ch	NULL
)	NULL
condensation	NULL
and	NULL
absence	NULL
of	NULL
nuclear	NULL
membrane	NULL
indicative	NULL
of	NULL
a	NULL
replicating	NULL
metaphase	NULL
nucleus	NULL
.	NULL

Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
EZ2F-1	NULL
BLOCKS	NULL
TERMINAL	NULL
DIFFERENTIATION	NULL
689	NULL
TABLE	NULL
1	NULL
.	NULL

E2F-1	NULL
transgenic	NULL
mice	NULL
do	NULL
not	NULL
respond	NULL
to	NULL
platelet	NULL
growth	NULL
factor	NULL
administration	NULL
Mean	NULL
no	NULL
.	NULL

of	NULL
platelets/pl	NULL
of	NULL
blood	NULL
+	NULL
SD	NULL
Cytokine	NULL
Mouse	NULL
%	NULL
Change	NULL
(	NULL
P	NULL
value	NULL
)	NULL
Before	NULL
treatment	NULL
After	NULL
treatment	NULL
MGDF	NULL
Nontransgenic	NULL
1,360,000	NULL
+	NULL
50,000	NULL
2,324,000	NULL
+	NULL
185,000	NULL
+71	NULL
(	NULL
<	NULL
0.01	NULL
)	NULL
PESI	NULL
219,000	NULL
+	NULL
120,000	NULL
192,000	NULL
+	NULL
111,000	NULL
NS	NULL
``	NULL
(	NULL
0.70	NULL
)	NULL
PES2	NULL
59,000	NULL
+	NULL
22,000	NULL
60,000	NULL
+	NULL
18,000	NULL
NS	NULL
(	NULL
0.92	NULL
)	NULL
IL-6	NULL
Nontransgenic	NULL
1,273,000	NULL
+	NULL
320,000	NULL
1,679,000	NULL
+	NULL
197,000	NULL
+32	NULL
(	NULL
0.05	NULL
)	NULL
PESI	NULL
255,000	NULL
+	NULL
69,000	NULL
167,000	NULL
+	NULL
63,000	NULL
NS	NULL
(	NULL
0.11	NULL
)	NULL
PES2	NULL
175,000	NULL
+	NULL
136,000	NULL
108,000	NULL
+	NULL
30,000	NULL
NS	NULL
(	NULL
0.36	NULL
)	NULL
``	NULL
NS	NULL
,	NULL
not	NULL
significant	NULL
.	NULL

granules	NULL
were	NULL
also	NULL
reduced	NULL
in	NULL
the	NULL
transgenic	NULL
mice	NULL
.	NULL

This	NULL
abnormal	NULL
membrane	NULL
formation	NULL
was	NULL
not	NULL
uniform	NULL
,	NULL
appearing	NULL
in	NULL
patches	NULL
throughout	NULL
the	NULL
megakaryocyte	NULL
cytoplasm	NULL
.	NULL

Such	NULL
structures	NULL
are	NULL
not	NULL
seen	NULL
in	NULL
normal	NULL
megakaryocytes	NULL
and	NULL
appear	NULL
to	NULL
be	NULL
inconsistent	NULL
with	NULL
nascent	NULL
platelet	NULL
formation	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
E2F-1	NULL
expression	NULL
in	NULL
megakaryocytes	NULL
acts	NULL
to	NULL
block	NULL
differentiation	NULL
during	NULL
the	NULL
postmitotic	NULL
maturation	NULL
phase	NULL
.	NULL

This	NULL
block	NULL
in	NULL
differentiation	NULL
precludes	NULL
the	NULL
formation	NULL
of	NULL
platelets	NULL
,	NULL
causing	NULL
extreme	NULL
thrombocytopenia	NULL
.	NULL

Transgenic	NULL
megakaryocytes	NULL
are	NULL
refractory	NULL
to	NULL
treatment	NULL
with	NULL
platelet	NULL
growth	NULL
factors	NULL
.	NULL

In	NULL
an	NULL
attempt	NULL
to	NULL
overcome	NULL
the	NULL
differentiation	NULL
block	NULL
observed	NULL
in	NULL
the	NULL
E2F-l-overexpressing	NULL
mice	NULL
,	NULL
five	NULL
animals	NULL
each	NULL
from	NULL
lines	NULL
PE82	NULL
and	NULL
PES1	NULL
along	NULL
with	NULL
five	NULL
negative	NULL
littermates	NULL
were	NULL
injected	NULL
daily	NULL
for	NULL
5	NULL
days	NULL
with	NULL
either	NULL
1	NULL
ug	NULL
of	NULL
recombinant	NULL
human	NULL
MGDF	NULL
or	NULL
10	NULL
ug	NULL
of	NULL
recombinant	NULL
human	NULL
interleukin	NULL
6	NULL
(	NULL
IL-6	NULL
)	NULL
.	NULL

Nontransgenic	NULL
mice	NULL
responded	NULL
predictably	NULL
to	NULL
both	NULL
treatments	NULL
,	NULL
exhibiting	NULL
a	NULL
70	NULL
%	NULL
increase	NULL
in	NULL
peripheral	NULL
platelet	NULL
count	NULL
in	NULL
response	NULL
to	NULL
MGDF	NULL
and	NULL
a	NULL
30	NULL
%	NULL
increase	NULL
in	NULL
response	NULL
to	NULL
IL-6	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
transgenic	NULL
lines	NULL
were	NULL
completely	NULL
refractory	NULL
to	NULL
either	NULL
MGDF	NULL
or	NULL
IL-6	NULL
administration	NULL
,	NULL
exhibiting	NULL
no	NULL
significant	NULL
change	NULL
in	NULL
circulating	NULL
platelet	NULL
levels	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
responsiveness	NULL
to	NULL
MGDF	NULL
was	NULL
not	NULL
due	NULL
to	NULL
the	NULL
absence	NULL
of	NULL
its	NULL
cognate	NULL
receptor	NULL
,	NULL
c-mpl	NULL
,	NULL
as	NULL
the	NULL
MGDF	NULL
receptor	NULL
was	NULL
confirmed	NULL
on	NULL
these	NULL
cells	NULL
by	NULL
immunohis-tochemistry	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Both	NULL
MGDF	NULL
and	NULL
IL-6	NULL
are	NULL
known	NULL
to	NULL
promote	NULL
differentiation	NULL
of	NULL
megakaryocytes	NULL
(	NULL
21	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
IL-6	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
terminal	NULL
differentiation	NULL
in	NULL
mature	NULL
megakaryocytes	NULL
(	NULL
1	NULL
)	NULL
.	NULL

It	NULL
appears	NULL
that	NULL
E2F-1	NULL
overexpression	NULL
acts	NULL
to	NULL
prevent	NULL
the	NULL
megakaryocytes	NULL
from	NULL
reaching	NULL
a	NULL
stage	NULL
of	NULL
maturation	NULL
at	NULL
which	NULL
they	NULL
are	NULL
able	NULL
to	NULL
respond	NULL
to	NULL
the	NULL
differentiative	NULL
signals	NULL
initiated	NULL
by	NULL
these	NULL
cytokines	NULL
.	NULL

E2F-1	NULL
causes	NULL
massive	NULL
megakaryocyte	NULL
accumulation	NULL
.	NULL

To	NULL
investigate	NULL
additional	NULL
changes	NULL
induced	NULL
by	NULL
overexpression	NULL
of	NULL
E2F-1	NULL
protein	NULL
,	NULL
PE82	NULL
was	NULL
chosen	NULL
for	NULL
further	NULL
analysis	NULL
.	NULL

Mice	NULL
from	NULL
this	NULL
line	NULL
exhibited	NULL
a	NULL
number	NULL
of	NULL
striking	NULL
characteristics	NULL
.	NULL

These	NULL
mice	NULL
lived	NULL
only	NULL
9	NULL
weeks	NULL
on	NULL
average	NULL
.	NULL

As	NULL
mice	NULL
aged	NULL
,	NULL
the	NULL
erythrocyte	NULL
count	NULL
often	NULL
decreased	NULL
.	NULL

Postmortem	NULL
examination	NULL
of	NULL
these	NULL
animals	NULL
revealed	NULL
evidence	NULL
of	NULL
internal	NULL
bleeding	NULL
,	NULL
perhaps	NULL
the	NULL
cause	NULL
of	NULL
death	NULL
.	NULL

Additionally	NULL
,	NULL
all	NULL
mice	NULL
examined	NULL
displayed	NULL
splenomegaly	NULL
,	NULL
up	NULL
to	NULL
approximately	NULL
10	NULL
times	NULL
normal	NULL
spleen	NULL
weight	NULL
,	NULL
as	NULL
well	NULL
as	NULL
grossly	NULL
enlarged	NULL
lymph	NULL
nodes	NULL
.	NULL

Hema-toxylin-and-eosin-stained	NULL
sections	NULL
of	NULL
decalcified	NULL
femurs	NULL
from	NULL
these	NULL
animals	NULL
revealed	NULL
increased	NULL
numbers	NULL
of	NULL
megakaryocytes	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
as	NULL
well	NULL
as	NULL
a	NULL
disruption	NULL
of	NULL
the	NULL
bone	NULL
marrow	NULL
architecture	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

The	NULL
bone	NULL
marrow	NULL
sinuses	NULL
were	NULL
greatly	NULL
enlarged	NULL
,	NULL
with	NULL
many	NULL
containing	NULL
megakaryocytes	NULL
.	NULL

Microscopic	NULL
examination	NULL
of	NULL
the	NULL
spleen	NULL
(	NULL
Fig	NULL
.	NULL

4D	NULL
)	NULL
and	NULL
lymph	NULL
node	NULL
(	NULL
Fig	NULL
.	NULL

4F	NULL
)	NULL
revealed	NULL
a	NULL
massive	NULL
accumulation	NULL
of	NULL
megakaryocytes	NULL
.	NULL

Megakaryocytes	NULL
in	NULL
the	NULL
spleen	NULL
were	NULL
primarily	NULL
found	NULL
in	NULL
the	NULL
red	NULL
pulp	NULL
and	NULL
at	NULL
the	NULL
subcapsular	NULL
region	NULL
of	NULL
the	NULL
tissue	NULL
.	NULL

In	NULL
the	NULL
lymph	NULL
node	NULL
,	NULL
a	NULL
tissue	NULL
normally	NULL
devoid	NULL
of	NULL
megakaryocytes	NULL
,	NULL
these	NULL
cells	NULL
were	NULL
observed	NULL
in	NULL
clusters	NULL
throughout	NULL
the	NULL
tissue	NULL
.	NULL

Megakaryocytes	NULL
were	NULL
also	NULL
found	NULL
in	NULL
the	NULL
blood	NULL
,	NULL
lungs	NULL
,	NULL
and	NULL
livers	NULL
of	NULL
these	NULL
animals	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
quantitate	NULL
the	NULL
number	NULL
of	NULL
megakaryocytes	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
and	NULL
spleen	NULL
,	NULL
cells	NULL
were	NULL
enumerated	NULL
by	NULL
microscopic	NULL
examination	NULL
of	NULL
tissue	NULL
sections	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

The	NULL
bone	NULL
marrow	NULL
exhibited	NULL
an	NULL
approximately	NULL
fivefold	NULL
increase	NULL
in	NULL
megakaryocyte	NULL
number	NULL
in	NULL
the	NULL
two	NULL
lines	NULL
examined	NULL
,	NULL
PE5S1	NULL
and	NULL
PE82	NULL
.	NULL

Megakaryocyte	NULL
numbers	NULL
in	NULL
the	NULL
spleen	NULL
were	NULL
increased	NULL
10-fold	NULL
in	NULL
the	NULL
same	NULL
lines	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
megakaryocyte	NULL
numbers	NULL
,	NULL
the	NULL
numbers	NULL
of	NULL
megakaryocyte	NULL
progenitor	NULL
cells	NULL
were	NULL
determined	NULL
by	NULL
quantitating	NULL
the	NULL
number	NULL
of	NULL
megakaryocyte	NULL
colony-forming	NULL
units	NULL
(	NULL
CFU-Meg	NULL
)	NULL
in	NULL
bone	NULL
marrow	NULL
of	NULL
PES1	NULL
and	NULL
PE82	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
the	NULL
number	NULL
of	NULL
CFU-Meg	NULL
was	NULL
increased	NULL
between	NULL
2.5-	NULL
and	NULL
4-fold	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
number	NULL
of	NULL
megakaryocyte	NULL
progenitors	NULL
was	NULL
increased	NULL
in	NULL
both	NULL
transgenic	NULL
lines	NULL
assayed	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
the	NULL
megakaryocytosis	NULL
was	NULL
restricted	NULL
to	NULL
the	NULL
adult	NULL
mice	NULL
,	NULL
fetuses	NULL
from	NULL
line	NULL
PE82	NULL
were	NULL
examined	NULL
at	NULL
day	NULL
15	NULL
postcoitus	NULL
.	NULL

Examination	NULL
of	NULL
embryonic	NULL
liver	NULL
,	NULL
the	NULL
site	NULL
of	NULL
hematopoiesis	NULL
during	NULL
fetal	NULL
development	NULL
,	NULL
revealed	NULL
increased	NULL
numbers	NULL
of	NULL
megakaryocytes	NULL
,	NULL
similar	NULL
to	NULL
the	NULL
phenotype	NULL
seen	NULL
in	NULL
adult	NULL
tissues	NULL
(	NULL
Fig	NULL
.	NULL

4H	NULL
)	NULL
.	NULL

Every	NULL
transgenic	NULL
mouse	NULL
in	NULL
the	NULL
litter	NULL
exhibited	NULL
the	NULL
phenotype	NULL
.	NULL

This	NULL
finding	NULL
demonstrates	NULL
that	NULL
the	NULL
onset	NULL
of	NULL
megakaryocytosis	NULL
is	NULL
at	NULL
least	NULL
coincident	NULL
with	NULL
early	NULL
fetal	NULL
hema-topoiesis	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
transgene	NULL
alone	NULL
is	NULL
sufficient	NULL
to	NULL
cause	NULL
the	NULL
phenotype	NULL
.	NULL

Interestingly	NULL
,	NULL
large	NULL
numbers	NULL
of	NULL
these	NULL
cells	NULL
do	NULL
not	NULL
remain	NULL
in	NULL
the	NULL
liver	NULL
after	NULL
hematopoiesis	NULL
moves	NULL
to	NULL
adult	NULL
tissues	NULL
.	NULL

Transgenic	NULL
megakaryocytes	NULL
are	NULL
eliminated	NULL
by	NULL
apoptosis	NULL
.	NULL

The	NULL
extent	NULL
of	NULL
megakaryocytosis	NULL
in	NULL
the	NULL
transgenic	NULL
mice	NULL
suggests	NULL
that	NULL
the	NULL
early	NULL
megakaryocytes	NULL
are	NULL
proliferating	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
megakaryocyte	NULL
accumulation	NULL
observed	NULL
is	NULL
due	NULL
to	NULL
increased	NULL
survival	NULL
of	NULL
cells	NULL
and	NULL
not	NULL
increased	NULL
proliferation	NULL
.	NULL

To	NULL
address	NULL
the	NULL
fate	NULL
of	NULL
the	NULL
transgenic	NULL
megakaryocytes	NULL
,	NULL
further	NULL
studies	NULL
were	NULL
performed	NULL
.	NULL

Microscopically	NULL
,	NULL
approximately	NULL
10	NULL
%	NULL
of	NULL
the	NULL
megakaryocytes	NULL
observed	NULL
appeared	NULL
to	NULL
have	NULL
nuclei	NULL
with	NULL
altered	NULL
staining	NULL
patterns	NULL
,	NULL
suggestive	NULL
of	NULL
the	NULL
appearance	NULL
of	NULL
apoptosis	NULL
.	NULL

Using	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
TUNEL	NULL
method	NULL
(	NULL
54	NULL
)	NULL
to	NULL
detect	NULL
DNA	NULL
fragmentation	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
apoptosis	NULL
was	NULL
confirmed	NULL
in	NULL
about	NULL
1/10	NULL
of	NULL
the	NULL
megakaryocytes	NULL
in	NULL
the	NULL
transgenic	NULL
spleen	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Examination	NULL
of	NULL
60	NULL
identifiable	NULL
megakaryocytes	NULL
in	NULL
normal	NULL
spleen	NULL
sections	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
and	NULL
D	NULL
)	NULL
revealed	NULL
no	NULL
evidence	NULL
of	NULL
apoptosis	NULL
,	NULL
suggesting	NULL
that	NULL
apoptosis	NULL
,	NULL
if	NULL
it	NULL
occurs	NULL
at	NULL
all	NULL
in	NULL
splenic	NULL
megakaryocytes	NULL
,	NULL
is	NULL
a	NULL
rare	NULL
event	NULL
.	NULL

Megakaryocytes	NULL
are	NULL
known	NULL
to	NULL
undergo	NULL
endomitosis	NULL
during	NULL
the	NULL
maturation	NULL
phase	NULL
,	NULL
resulting	NULL
in	NULL
increases	NULL
in	NULL
DNA	NULL
content	NULL
up	NULL
to	NULL
128N	NULL
(	NULL
18	NULL
)	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
such	NULL
amplification	NULL
of	NULL
DNA	NULL
leads	NULL
to	NULL
a	NULL
positive	NULL
signal	NULL
,	NULL
using	NULL
the	NULL
TUNEL	NULL
technique	NULL
.	NULL

However	NULL
,	NULL
because	NULL
no	NULL
signal	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
nontransgenic	NULL
megakaryocytes	NULL
,	NULL
we	NULL
consider	NULL
it	NULL
unlikely	NULL
that	NULL
the	NULL
signal	NULL
observed	NULL
in	NULL
a	NULL
subset	NULL
of	NULL
the	NULL
transgenic	NULL
cells	NULL
is	NULL
the	NULL
result	NULL
of	NULL
endomitosis	NULL
.	NULL

Preliminary	NULL
ultra-structure	NULL
observations	NULL
using	NULL
electron	NULL
microscopy	NULL
revealed	NULL
cells	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

FIG	NULL
.	NULL

4	NULL
.	NULL

Proliferation	NULL
of	NULL
megakaryocytes	NULL
in	NULL
various	NULL
tissues	NULL
from	NULL
E2F-1-expressing	NULL
mice	NULL
.	NULL

(	NULL
A	NULL
,	NULL
C	NULL
,	NULL
E	NULL
,	NULL
and	NULL
G	NULL
)	NULL
Wild	NULL
type	NULL
;	NULL
(	NULL
B	NULL
,	NULL
D	NULL
,	NULL
F	NULL
,	NULL
and	NULL
H	NULL
)	NULL
transgenic	NULL
PE82	NULL
.	NULL

(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
Bone	NULL
marrow	NULL
;	NULL
(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
spleen	NULL
;	NULL
(	NULL
E	NULL
and	NULL
F	NULL
)	NULL
lymph	NULL
node	NULL
;	NULL
(	NULL
G	NULL
and	NULL
H	NULL
)	NULL
embryonic	NULL
day	NULL
15	NULL
liver	NULL
.	NULL

Representative	NULL
megakaryocytes	NULL
are	NULL
indicated	NULL
in	NULL
each	NULL
panel	NULL
by	NULL
arrows	NULL
.	NULL

Photomicrographs	NULL
were	NULL
taken	NULL
of	NULL
hematoxylin-and-cosin-stained	NULL
4-p.m	NULL
sections	NULL
of	NULL
the	NULL
indicated	NULL
tissues	NULL
.	NULL

Note	NULL
the	NULL
abundance	NULL
of	NULL
megakaryocytes	NULL
in	NULL
the	NULL
transgenic	NULL
tissues	NULL
compared	NULL
with	NULL
normal	NULL
tissues	NULL
.	NULL

Magnification	NULL
,	NULL
x86	NULL
.	NULL

Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
A	NULL
»	NULL
5	NULL
200	NULL
E=l	NULL
$	NULL
``	NULL
150-2	NULL
€	NULL
fed	NULL
3	NULL
1007	NULL
2	NULL
E	NULL
E	NULL
T	NULL
s	NULL
504	NULL
IT	NULL
2	NULL
0-	NULL
8	NULL
40	NULL
<	NULL
<	NULL
£	NULL
i	NULL
$	NULL
$	NULL
2A	NULL
da	NULL
a	NULL
&	NULL
0	NULL
%	NULL
C	NULL
r	NULL
©	NULL
ma	NULL
8	NULL
uy	NULL
go	NULL
o	NULL
a	NULL
a	NULL
§	NULL
E	NULL
£	NULL
g	NULL
2	NULL
B	NULL
500	NULL
3	NULL
§	NULL
400	NULL
I~	NULL
2	NULL
G	NULL
300-7	NULL
o	NULL
E	NULL
]	NULL
s	NULL
200	NULL
o	NULL
E	NULL
§	NULL
100-c	NULL
0	NULL
Control	NULL
PES1	NULL
PE82	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Megakaryocyte	NULL
number	NULL
and	NULL
CFU-Meg	NULL
are	NULL
increased	NULL
in	NULL
E2F-1-expressing	NULL
mice	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Megakaryocyte	NULL
numbers	NULL
in	NULL
bone	NULL
marrow	NULL
(	NULL
B.M	NULL
.	NULL
)	NULL

and	NULL
spleen	NULL
sections	NULL
of	NULL
PE51	NULL
,	NULL
PE82	NULL
,	NULL
and	NULL
wild-type	NULL
mice	NULL
.	NULL

The	NULL
number	NULL
of	NULL
megakaryocytes	NULL
(	NULL
meg	NULL
)	NULL
per	NULL
field	NULL
was	NULL
determined	NULL
and	NULL
plotted	NULL
as	NULL
cells	NULL
per	NULL
section	NULL
.	NULL

At	NULL
least	NULL
50	NULL
megakaryocytes	NULL
were	NULL
counted	NULL
per	NULL
line	NULL
.	NULL

The	NULL
data	NULL
are	NULL
presented	NULL
as	NULL
means	NULL
+	NULL
SDs	NULL
of	NULL
at	NULL
least	NULL
three	NULL
animals	NULL
per	NULL
line	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Megakaryocyte	NULL
progenitor	NULL
numbers	NULL
in	NULL
bone	NULL
marrow	NULL
of	NULL
PES1	NULL
,	NULL
PE82	NULL
,	NULL
and	NULL
wild-type	NULL
mice	NULL
.	NULL

The	NULL
number	NULL
of	NULL
colonies	NULL
containing	NULL
large	NULL
acetylcholinesterase-positive	NULL
cells	NULL
grown	NULL
in	NULL
soft	NULL
agar	NULL
was	NULL
determined	NULL
and	NULL
plotted	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
wild-type	NULL
values	NULL
+	NULL
the	NULL
percent	NULL
SD	NULL
.	NULL

P	NULL
was	NULL
<	NULL
0.01	NULL
for	NULL
both	NULL
PE51	NULL
and	NULL
PE82	NULL
relative	NULL
to	NULL
controls	NULL
.	NULL

with	NULL
apoptotic	NULL
characteristics	NULL
,	NULL
providing	NULL
support	NULL
for	NULL
this	NULL
conclusion	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
large	NULL
numbers	NULL
of	NULL
megakaryocytes	NULL
in	NULL
normal	NULL
and	NULL
ectopic	NULL
sites	NULL
,	NULL
combined	NULL
with	NULL
the	NULL
rapid	NULL
removal	NULL
of	NULL
megakaryocytes	NULL
through	NULL
apoptosis	NULL
,	NULL
provides	NULL
strong	NULL
evidence	NULL
that	NULL
the	NULL
transgene	NULL
is	NULL
stimulating	NULL
a	NULL
dramatic	NULL
increase	NULL
in	NULL
megakaryocyte	NULL
production	NULL
.	NULL

DISCUSSION	NULL
The	NULL
decision	NULL
between	NULL
proliferation	NULL
and	NULL
differentiation	NULL
requires	NULL
the	NULL
concerted	NULL
activity	NULL
of	NULL
genes	NULL
that	NULL
regulate	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Although	NULL
E2F-1	NULL
is	NULL
known	NULL
to	NULL
have	NULL
a	NULL
positive	NULL
effect	NULL
on	NULL
cell	NULL
division	NULL
in	NULL
vitro	NULL
(	NULL
24	NULL
,	NULL
26	NULL
,	NULL
51	NULL
)	NULL
,	NULL
the	NULL
data	NULL
presented	NULL
here	NULL
demonstrate	NULL
that	NULL
E2F-1	NULL
can	NULL
both	NULL
stimulate	NULL
cell	NULL
division	NULL
and	NULL
modulate	NULL
the	NULL
differentiative	NULL
potential	NULL
of	NULL
a	NULL
cell	NULL
in	NULL
vivo	NULL
.	NULL

E2F-1	NULL
expression	NULL
in	NULL
the	NULL
megakaryocyte	NULL
lineage	NULL
leads	NULL
to	NULL
greatly	NULL
increased	NULL
numbers	NULL
of	NULL
mature	NULL
megakaryocytes	NULL
.	NULL

However	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
the	NULL
differentiative	NULL
capacity	NULL
of	NULL
these	NULL
cells	NULL
is	NULL
reduced	NULL
,	NULL
causing	NULL
arrest	NULL
during	NULL
the	NULL
maturation	NULL
phase	NULL
.	NULL

Agents	NULL
known	NULL
to	NULL
positively	NULL
affect	NULL
terminal	NULL
differentiation	NULL
of	NULL
megakaryocytes	NULL
can	NULL
not	NULL
function	NULL
to	NULL
bypass	NULL
the	NULL
differentiation	NULL
block	NULL
.	NULL

Because	NULL
these	NULL
megakaryocytes	NULL
EZ2F-1	NULL
BLOCKS	NULL
TERMINAL	NULL
DIFFERENTIATION	NULL
691	NULL
can	NULL
not	NULL
terminally	NULL
differentiate	NULL
into	NULL
platelets	NULL
,	NULL
they	NULL
appear	NULL
to	NULL
die	NULL
through	NULL
an	NULL
apoptotic	NULL
pathway	NULL
.	NULL

E2F-1	NULL
has	NULL
been	NULL
shown	NULL
previously	NULL
to	NULL
cooperate	NULL
with	NULL
p53	NULL
to	NULL
induce	NULL
apoptosis	NULL
in	NULL
cultured	NULL
cells	NULL
(	NULL
41	NULL
,	NULL
48	NULL
,	NULL
57	NULL
)	NULL
.	NULL

Such	NULL
a	NULL
scenario	NULL
fits	NULL
with	NULL
the	NULL
``	NULL
clash	NULL
``	NULL
hypothesis	NULL
in	NULL
which	NULL
conflicting	NULL
signals	NULL
of	NULL
growth	NULL
and	NULL
growth	NULL
arrest	NULL
cause	NULL
entry	NULL
into	NULL
the	NULL
apoptotic	NULL
pathway	NULL
(	NULL
8	NULL
)	NULL
.	NULL

The	NULL
complete	NULL
pen-etrance	NULL
and	NULL
the	NULL
early	NULL
onset	NULL
of	NULL
the	NULL
phenotype	NULL
suggest	NULL
that	NULL
the	NULL
megakaryocytosis	NULL
is	NULL
likely	NULL
due	NULL
solely	NULL
to	NULL
the	NULL
effects	NULL
of	NULL
E2F-1	NULL
expression	NULL
and	NULL
not	NULL
due	NULL
to	NULL
secondary	NULL
events	NULL
or	NULL
mutations	NULL
.	NULL

The	NULL
megakaryocyte	NULL
accumulation	NULL
seen	NULL
in	NULL
these	NULL
animals	NULL
could	NULL
result	NULL
from	NULL
either	NULL
increased	NULL
production	NULL
of	NULL
early	NULL
PF4-positive	NULL
cells	NULL
(	NULL
proliferation	NULL
)	NULL
or	NULL
increased	NULL
survival	NULL
of	NULL
the	NULL
megakaryocytes	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
the	NULL
cells	NULL
are	NULL
rapidly	NULL
being	NULL
removed	NULL
through	NULL
apoptosis	NULL
suggests	NULL
that	NULL
there	NULL
is	NULL
increased	NULL
production	NULL
of	NULL
megakaryocytes	NULL
.	NULL

However	NULL
,	NULL
because	NULL
these	NULL
mice	NULL
are	NULL
severely	NULL
thrombocytopenic	NULL
,	NULL
endogenous	NULL
mechanisms	NULL
should	NULL
be	NULL
acting	NULL
to	NULL
increase	NULL
the	NULL
number	NULL
and	NULL
size	NULL
of	NULL
the	NULL
megakaryocytes	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Such	NULL
mechanisms	NULL
do	NULL
not	NULL
appear	NULL
to	NULL
account	NULL
for	NULL
the	NULL
massive	NULL
accumulation	NULL
observed	NULL
in	NULL
the	NULL
EZF-1	NULL
transgenic	NULL
mice	NULL
.	NULL

Three	NULL
other	NULL
mouse	NULL
models	NULL
of	NULL
severe	NULL
thrombocytopenia	NULL
that	NULL
have	NULL
been	NULL
described	NULL
report	NULL
two-	NULL
to	NULL
fourfold	NULL
increases	NULL
in	NULL
bone	NULL
marrow	NULL
megakaryocyte	NULL
numbers	NULL
(	NULL
38	NULL
,	NULL
44	NULL
,	NULL
50	NULL
)	NULL
,	NULL
similar	NULL
to	NULL
the	NULL
fivefold	NULL
increase	NULL
seen	NULL
in	NULL
the	NULL
E2F-1-expressing	NULL
mice	NULL
.	NULL

However	NULL
,	NULL
the	NULL
E2F-1-expressing	NULL
mice	NULL
also	NULL
have	NULL
10-fold	NULL
increases	NULL
in	NULL
the	NULL
number	NULL
of	NULL
splenic	NULL
megakaryocytes	NULL
as	NULL
well	NULL
as	NULL
infiltration	NULL
of	NULL
megakaryocytes	NULL
into	NULL
ectopic	NULL
sites	NULL
such	NULL
as	NULL
the	NULL
lymph	NULL
node	NULL
and	NULL
liver	NULL
.	NULL

Such	NULL
numbers	NULL
and	NULL
distribution	NULL
of	NULL
megakaryocytes	NULL
have	NULL
not	NULL
been	NULL
observed	NULL
in	NULL
the	NULL
other	NULL
thrombocytopenia	NULL
models	NULL
,	NULL
suggesting	NULL
that	NULL
there	NULL
is	NULL
some	NULL
additional	NULL
proliferative	NULL
signal	NULL
in	NULL
the	NULL
E2F-1-expressing	NULL
mice	NULL
.	NULL

We	NULL
therefore	NULL
postulate	NULL
that	NULL
E2F-1	NULL
is	NULL
able	NULL
to	NULL
increase	NULL
the	NULL
number	NULL
of	NULL
cell	NULL
divisions	NULL
in	NULL
the	NULL
committed	NULL
precursor	NULL
cells	NULL
.	NULL

Although	NULL
E2F-1	NULL
appears	NULL
to	NULL
stimulate	NULL
increased	NULL
proliferation	NULL
of	NULL
megakaryocyte	NULL
precursors	NULL
,	NULL
it	NULL
is	NULL
unable	NULL
to	NULL
prevent	NULL
the	NULL
cells	NULL
from	NULL
initiating	NULL
differentiation	NULL
.	NULL

This	NULL
is	NULL
likely	NULL
due	NULL
to	NULL
the	NULL
temporal	NULL
onset	NULL
of	NULL
PF4	NULL
promoter	NULL
function	NULL
,	NULL
occurring	NULL
as	NULL
megakaryocyte	NULL
precursors	NULL
are	NULL
entering	NULL
a	NULL
differentiative	NULL
phase	NULL
.	NULL

Despite	NULL
expression	NULL
of	NULL
E2F-1	NULL
,	NULL
these	NULL
committed	NULL
precursors	NULL
can	NULL
exit	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
give	NULL
rise	NULL
to	NULL
postmitotic	NULL
,	NULL
albeit	NULL
abnormal	NULL
megakaryocytes	NULL
.	NULL

Targeting	NULL
expression	NULL
of	NULL
E2F-1	NULL
to	NULL
mitotic	NULL
progenitor	NULL
cells	NULL
would	NULL
address	NULL
whether	NULL
the	NULL
protein	NULL
could	NULL
prevent	NULL
differentiation	NULL
into	NULL
megakaryocytes	NULL
.	NULL

Previous	NULL
experiments	NULL
suggest	NULL
that	NULL
Rb	NULL
may	NULL
be	NULL
important	NULL
for	NULL
differentiation	NULL
of	NULL
this	NULL
lineage	NULL
,	NULL
as	NULL
megakaryocytes	NULL
from	NULL
mice	NULL
expressing	NULL
a	NULL
megakaryocyte-targeted	NULL
simian	NULL
virus	NULL
40	NULL
tempera-ture-sensitive	NULL
large	NULL
T	NULL
antigen	NULL
were	NULL
unable	NULL
to	NULL
terminally	NULL
differentiate	NULL
(	NULL
44	NULL
)	NULL
.	NULL

A	NULL
possible	NULL
mechanism	NULL
to	NULL
explain	NULL
the	NULL
phenotypes	NULL
observed	NULL
in	NULL
both	NULL
of	NULL
these	NULL
mice	NULL
stipulates	NULL
an	NULL
interaction	NULL
between	NULL
Rb	NULL
and	NULL
E2F-1	NULL
to	NULL
control	NULL
differentiation	NULL
.	NULL

We	NULL
propose	NULL
that	NULL
Rb	NULL
,	NULL
known	NULL
to	NULL
be	NULL
present	NULL
in	NULL
megakaryocytes	NULL
(	NULL
55	NULL
)	NULL
,	NULL
allows	NULL
the	NULL
cell	NULL
to	NULL
differentiate	NULL
through	NULL
inhibition	NULL
of	NULL
EZF	NULL
transcriptional	NULL
activity	NULL
.	NULL

An	NULL
increase	NULL
of	NULL
active	NULL
E2F-1	NULL
(	NULL
either	NULL
through	NULL
overexpression	NULL
or	NULL
by	NULL
blocking	NULL
Rb	NULL
)	NULL
prevents	NULL
the	NULL
cell	NULL
from	NULL
terminally	NULL
differentiating	NULL
.	NULL

This	NULL
cell	NULL
,	NULL
receiving	NULL
conflicting	NULL
signals	NULL
of	NULL
differentiation	NULL
and	NULL
proliferation	NULL
,	NULL
activates	NULL
an	NULL
apoptotic	NULL
pathway	NULL
leading	NULL
to	NULL
cell	NULL
death	NULL
.	NULL

It	NULL
is	NULL
formally	NULL
possible	NULL
that	NULL
E2F-1	NULL
functions	NULL
not	NULL
as	NULL
a	NULL
transcriptional	NULL
activator	NULL
but	NULL
only	NULL
to	NULL
bind	NULL
and	NULL
inactivate	NULL
Rb	NULL
.	NULL

Transgenic	NULL
expression	NULL
of	NULL
E2F-1	NULL
mutants	NULL
deficient	NULL
for	NULL
either	NULL
Rb	NULL
binding	NULL
or	NULL
transcription	NULL
would	NULL
be	NULL
required	NULL
to	NULL
rule	NULL
out	NULL
this	NULL
possibility	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
the	NULL
dramatic	NULL
effects	NULL
of	NULL
deregulation	NULL
of	NULL
the	NULL
E2F-1	NULL
protein	NULL
in	NULL
vivo	NULL
and	NULL
suggest	NULL
that	NULL
the	NULL
cell	NULL
cycle-regulatory	NULL
proteins	NULL
,	NULL
CDKs	NULL
,	NULL
CDK	NULL
inhibitors	NULL
,	NULL
and	NULL
Rb	NULL
function	NULL
to	NULL
control	NULL
differentiation	NULL
through	NULL
modulation	NULL
of	NULL
E2F	NULL
activity	NULL
.	NULL

Furthermore	NULL
,	NULL
this	NULL
mouse	NULL
may	NULL
serve	NULL
as	NULL
a	NULL
useful	NULL
tool	NULL
to	NULL
692	NULL
GUY	NULL
ET	NULL
AL	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

FIG	NULL
.	NULL

6	NULL
.	NULL

In	NULL
situ	NULL
detection	NULL
of	NULL
apoptotic	NULL
megakaryocytes	NULL
in	NULL
the	NULL
spleens	NULL
of	NULL
E2F-1	NULL
transgenic	NULL
animals	NULL
.	NULL

Approximately	NULL
10	NULL
%	NULL
of	NULL
the	NULL
megakaryocytes	NULL
in	NULL
the	NULL
spleen	NULL
sections	NULL
of	NULL
E2F-1-expressing	NULL
mice	NULL
presented	NULL
direct	NULL
evidence	NULL
of	NULL
cell	NULL
death	NULL
,	NULL
whereas	NULL
none	NULL
were	NULL
detected	NULL
in	NULL
the	NULL
normal	NULL
animal	NULL
.	NULL

(	NULL
A	NULL
and	NULL
C	NULL
)	NULL
PE82	NULL
spleen	NULL
;	NULL
(	NULL
B	NULL
and	NULL
D	NULL
)	NULL
wild-type	NULL
spleen	NULL
.	NULL

Arrowheads	NULL
indicate	NULL
apoptotic	NULL
megakaryocytes	NULL
.	NULL

m	NULL
,	NULL
nonapoptotic	NULL
megakaryocyte	NULL
.	NULL

Magnifications	NULL
:	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
ca	NULL
.	NULL

x18	NULL
;	NULL
(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
x71	NULL
.	NULL

develop	NULL
reagents	NULL
that	NULL
impair	NULL
E2F-1	NULL
function	NULL
,	NULL
reagents	NULL
that	NULL
may	NULL
have	NULL
a	NULL
therapeutic	NULL
use	NULL
in	NULL
cancer	NULL
treatment	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
W.	NULL
Kaelin	NULL
for	NULL
the	NULL
generous	NULL
gift	NULL
of	NULL
the	NULL
E2F-1	NULL
cDNA	NULL
,	NULL
D.	NULL
Dureya	NULL
for	NULL
histology	NULL
,	NULL
T.	NULL
Paschke	NULL
and	NULL
K.	NULL
Klopchin	NULL
for	NULL
assistance	NULL
with	NULL
transgenic	NULL
mice	NULL
,	NULL
T.	NULL
Boone	NULL
for	NULL
providing	NULL
MGDF	NULL
,	NULL
G.	NULL
Elliot	NULL
for	NULL
confocal	NULL
microscopy	NULL
,	NULL
and	NULL
B.	NULL
Bosselman	NULL
,	NULL
F.	NULL
Calzone	NULL
,	NULL
and	NULL
A.	NULL
Welcher	NULL
for	NULL
critical	NULL
review	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

C.	NULL
Guy	NULL
was	NULL
supported	NULL
by	NULL
an	NULL
Amgen	NULL
postdoctoral	NULL
fellowship	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

An	NULL
,	NULL
E.	NULL
,	NULL
K.	NULL
Ogata	NULL
,	NULL
S.	NULL
Kuriya	NULL
,	NULL
and	NULL
T.	NULL
Nomura	NULL
.	NULL

1994	NULL
.	NULL

Interleukin-6	NULL
and	NULL
eryth-ropoietin	NULL
act	NULL
as	NULL
direct	NULL
potentiators	NULL
and	NULL
inducers	NULL
of	NULL
in	NULL
vitro	NULL
cytoplasmic	NULL
process	NULL
formation	NULL
on	NULL
purified	NULL
mouse	NULL
megakaryocytes	NULL
.	NULL

Exp	NULL
.	NULL

Hematol	NULL
.	NULL

22	NULL
:	NULL
149-156	NULL
.	NULL

2	NULL
.	NULL

Bandara	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
V.	NULL
M.	NULL
Buck	NULL
,	NULL
M.	NULL
Zamanian	NULL
,	NULL
L.	NULL
H.	NULL
Johnston	NULL
,	NULL
and	NULL
N.	NULL
B	NULL
.	NULL

La	NULL
Thangue	NULL
.	NULL

1993	NULL
.	NULL

Functional	NULL
synergy	NULL
between	NULL
DP-1	NULL
and	NULL
E2F-1	NULL
in	NULL
the	NULL
cell	NULL
cycle-regulating	NULL
transcription	NULL
factor	NULL
DRTFI/E2F	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:4317-4324	NULL
.	NULL

3	NULL
.	NULL

Bartley	NULL
,	NULL
T.	NULL
D.	NULL
,	NULL
J.	NULL
Bogenberger	NULL
,	NULL
P.	NULL
Hunt	NULL
,	NULL
Y.	NULL
S.	NULL
Li	NULL
,	NULL
H.	NULL
S.	NULL
Lu	NULL
,	NULL
F.	NULL
Martin	NULL
,	NULL
M.	NULL
S.	NULL
Chang	NULL
,	NULL
B.	NULL
Samal	NULL
,	NULL
J.	NULL
L.	NULL
Nichol	NULL
,	NULL
S.	NULL
Swift	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
.	NULL

Identification	NULL
and	NULL
cloning	NULL
of	NULL
a	NULL
megakaryocyte	NULL
growth	NULL
and	NULL
development	NULL
factor	NULL
that	NULL
is	NULL
a	NULL
ligand	NULL
for	NULL
the	NULL
cytokine	NULL
receptor	NULL
Mpl	NULL
.	NULL

Cell	NULL
77:1117-1124	NULL
.	NULL

4	NULL
.	NULL

Beijersbergen	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
R.	NULL
M.	NULL
Kerkhoven	NULL
,	NULL
L.	NULL
Zhu	NULL
,	NULL
L.	NULL
Carlee	NULL
,	NULL
P.	NULL
M.	NULL
Voorhoeve	NULL
,	NULL
and	NULL
R.	NULL
Bernards	NULL
.	NULL

1994	NULL
.	NULL

E2F-4	NULL
,	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
E2F	NULL
gene	NULL
family	NULL
,	NULL
has	NULL
oncogenic	NULL
activity	NULL
and	NULL
associates	NULL
with	NULL
p107	NULL
in	NULL
vivo	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

8:2680-2690	NULL
.	NULL

5	NULL
.	NULL

Clarke	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
E.	NULL
R.	NULL
Maandag	NULL
,	NULL
M.	NULL
van	NULL
Roon	NULL
,	NULL
N.	NULL
M.	NULL
T.	NULL
van	NULL
der	NULL
Lugt	NULL
,	NULL
M.	NULL
van	NULL
der	NULL
Valk	NULL
,	NULL
M.	NULL
L.	NULL
Hooper	NULL
,	NULL
A.	NULL
Berns	NULL
,	NULL
and	NULL
H.	NULL
te	NULL
Riele	NULL
.	NULL

1992	NULL
.	NULL

Requirement	NULL
for	NULL
a	NULL
functional	NULL
Rb-1	NULL
gene	NULL
in	NULL
murine	NULL
development	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
359:328-330	NULL
.	NULL

6	NULL
.	NULL

Dimari	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
E.	NULL
Hara	NULL
,	NULL
and	NULL
J.	NULL
Campisi	NULL
.	NULL

1994	NULL
.	NULL

Regulation	NULL
of	NULL
two	NULL
E2F-related	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16.	NULL
genes	NULL
in	NULL
presenescent	NULL
and	NULL
senescent	NULL
human	NULL
fibroblasts	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
:	NULL
16180-16186.	NULL
.	NULL

Dou	NULL
,	NULL
Q.	NULL
P.	NULL
,	NULL
S.	NULL
Zhao	NULL
,	NULL
A.	NULL
H.	NULL
Levin	NULL
,	NULL
J.	NULL
Wang	NULL
,	NULL
K.	NULL
Helin	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Pardee	NULL
.	NULL

1994	NULL
.	NULL

G1/S-regulated	NULL
E2F-containing	NULL
protein	NULL
complexes	NULL
bind	NULL
to	NULL
the	NULL
mouse	NULL
thymidine	NULL
kinase	NULL
gene	NULL
promoter	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:1306-1313.	NULL
.	NULL

Fisher	NULL
,	NULL
D.	NULL
E.	NULL
1994	NULL
.	NULL

Apoptosis	NULL
in	NULL
cancer	NULL
therapy	NULL
:	NULL
crossing	NULL
the	NULL
threshold	NULL
.	NULL

Cell	NULL
78:539-542.	NULL
.	NULL

Flemington	NULL
,	NULL
E.	NULL
K.	NULL
,	NULL
S.	NULL
H.	NULL
Speck	NULL
,	NULL
and	NULL
W.	NULL
G.	NULL
Kaelin	NULL
,	NULL
Jr.	NULL
1993	NULL
.	NULL

E2F	NULL
--	NULL
mediated	NULL
transactivation	NULL
is	NULL
inhibited	NULL
by	NULL
complex	NULL
formation	NULL
with	NULL
the	NULL
retinoblastoma	NULL
susceptibility	NULL
gene	NULL
product	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:6914-6918	NULL
.	NULL

Gewirtz	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
M.	NULL
Ponez	NULL
.	NULL

1991	NULL
.	NULL

Megakaryocytopoiesis	NULL
and	NULL
platelet	NULL
production	NULL
,	NULL
p.	NULL
1148-1157	NULL
.	NULL

In	NULL
R.	NULL
Hoffman	NULL
,	NULL
E.	NULL
J.	NULL
Benz	NULL
,	NULL
S.	NULL
J.	NULL
Shattil	NULL
,	NULL
B.	NULL
Furie	NULL
,	NULL
and	NULL
H.	NULL
J.	NULL
Cohen	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Hematology	NULL
:	NULL
basic	NULL
principles	NULL
and	NULL
practice	NULL
.	NULL

Churchill	NULL
Livingstone	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Ginsberg	NULL
,	NULL
D.	NULL
,	NULL
G.	NULL
Vairo	NULL
,	NULL
T.	NULL
Chittenden	NULL
,	NULL
Z.	NULL
X.	NULL
Xiao	NULL
,	NULL
G.	NULL
Xu	NULL
,	NULL
K.	NULL
L.	NULL
Wydner	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
DeCaprio	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Lawrence	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
Livingston	NULL
.	NULL

1994	NULL
.	NULL

E2F-4	NULL
,	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
E2F	NULL
transcription	NULL
factor	NULL
family	NULL
,	NULL
interacts	NULL
with	NULL
p107	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

8	NULL
:	NULL
2665-2679	NULL
.	NULL

Girling	NULL
,	NULL
R.	NULL
,	NULL
J.	NULL
F.	NULL
Partridge	NULL
,	NULL
L.	NULL
R.	NULL
Bandara	NULL
,	NULL
N.	NULL
Burden	NULL
,	NULL
N.	NULL
F.	NULL
Totty	NULL
,	NULL
J.	NULL
J.	NULL
Hsuan	NULL
,	NULL
and	NULL
N.	NULL
B	NULL
.	NULL

La	NULL
Thangue	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
new	NULL
component	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
DRTFI/E2F	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
362:83-87	NULL
.	NULL

Gu	NULL
,	NULL
W.	NULL
,	NULL
J.	NULL
W.	NULL
Schneider	NULL
,	NULL
G.	NULL
Condorelli	NULL
,	NULL
S.	NULL
Kaushal	NULL
,	NULL
V.	NULL
Mahdavi	NULL
,	NULL
and	NULL
B.	NULL
Nadal	NULL
Ginard	NULL
.	NULL

1993	NULL
.	NULL

Interaction	NULL
of	NULL
myogenic	NULL
factors	NULL
and	NULL
the	NULL
retinoblastoma	NULL
protein	NULL
mediates	NULL
muscle	NULL
cell	NULL
commitment	NULL
and	NULL
differentiation	NULL
.	NULL

Cell	NULL
72:309-324	NULL
.	NULL

Halevy	NULL
,	NULL
O.	NULL
,	NULL
B.	NULL
G.	NULL
Novitch	NULL
,	NULL
D.	NULL
B.	NULL
Spicer	NULL
,	NULL
S.	NULL
X.	NULL
Skapek	NULL
,	NULL
J.	NULL
Rhee	NULL
,	NULL
G.	NULL
J.	NULL
Hannon	NULL
,	NULL
D.	NULL
Beach	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Lassar	NULL
.	NULL

1995	NULL
.	NULL

Correlation	NULL
of	NULL
terminal	NULL
cell	NULL
cycle	NULL
arrest	NULL
of	NULL
skeletal	NULL
muscle	NULL
with	NULL
induction	NULL
of	NULL
p21	NULL
by	NULL
MyoD	NULL
.	NULL

Science	NULL
267:1018-1021	NULL
.	NULL

Helin	NULL
,	NULL
K.	NULL
,	NULL
E.	NULL
Harlow	NULL
,	NULL
and	NULL
A.	NULL
Fattaey	NULL
.	NULL

1993	NULL
.	NULL

Inhibition	NULL
of	NULL
E2F-1	NULL
transactivation	NULL
by	NULL
direct	NULL
binding	NULL
of	NULL
the	NULL
retinoblastoma	NULL
protein	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
:	NULL
6501-6508	NULL
.	NULL

Helin	NULL
,	NULL
K.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Lees	NULL
,	NULL
M.	NULL
Vidal	NULL
,	NULL
N.	NULL
Dyson	NULL
,	NULL
E.	NULL
Harlow	NULL
,	NULL
and	NULL
A.	NULL
Fattaey	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
cDNA	NULL
encoding	NULL
a	NULL
pRB-binding	NULL
protein	NULL
with	NULL
properties	NULL
of	NULL
the	NULL
transcrip-	NULL
Vou	NULL
.	NULL

16	NULL
,	NULL
1996	NULL
17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38.	NULL
tion	NULL
factor	NULL
E2F	NULL
.	NULL

Cell	NULL
70:337-350	NULL
.	NULL

Helin	NULL
,	NULL
K.	NULL
,	NULL
C.	NULL
L.	NULL
Wu	NULL
,	NULL
A.	NULL
R.	NULL
Fattaey	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Lees	NULL
,	NULL
B.	NULL
D.	NULL
Dynlacht	NULL
,	NULL
C.	NULL
Ngwu	NULL
,	NULL
and	NULL
E.	NULL
Harlow	NULL
.	NULL

1993	NULL
.	NULL

Heterodimerization	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
E2F-1	NULL
and	NULL
DP-1	NULL
leads	NULL
to	NULL
cooperative	NULL
trans-activation	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:1850-1861	NULL
.	NULL

Hoffman	NULL
,	NULL
R.	NULL
1989	NULL
.	NULL

Regulation	NULL
of	NULL
megakaryocytopoiesis	NULL
.	NULL

Blood	NULL
74:119	NULL
%	NULL
6-1212	NULL
.	NULL

Hogan	NULL
,	NULL
B.	NULL
,	NULL
F.	NULL
Costantini	NULL
,	NULL
and	NULL
E.	NULL
Lacy	NULL
.	NULL

1986	NULL
.	NULL

Manipulating	NULL
the	NULL
mouse	NULL
em-bryo	NULL
:	NULL
a	NULL
laboratory	NULL
manual	NULL
,	NULL
p.	NULL
152-182	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
N.Y.	NULL
Hsiao	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
S.	NULL
L.	NULL
McMahon	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farnham	NULL
.	NULL

1994	NULL
.	NULL

Multiple	NULL
DNA	NULL
elements	NULL
are	NULL
required	NULL
for	NULL
the	NULL
growth	NULL
regulation	NULL
of	NULL
the	NULL
mouse	NULL
E2F1	NULL
promoter	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

8:1526-1537	NULL
.	NULL

Ishibashi	NULL
,	NULL
T.	NULL
,	NULL
H.	NULL
Kimura	NULL
,	NULL
Y.	NULL
Shikama	NULL
,	NULL
T.	NULL
Uchida	NULL
,	NULL
S.	NULL
Kariyone	NULL
,	NULL
T.	NULL
Hirano	NULL
,	NULL
T.	NULL
Kishimoto	NULL
,	NULL
F.	NULL
Takatsuki	NULL
,	NULL
and	NULL
Y.	NULL
Akiyama	NULL
.	NULL

1989	NULL
.	NULL

Interleukin-6	NULL
is	NULL
a	NULL
potent	NULL
thrombopoietic	NULL
factor	NULL
in	NULL
vivo	NULL
in	NULL
mice	NULL
.	NULL

Blood	NULL
74:1241-1244	NULL
.	NULL

Ivey	NULL
,	NULL
H.-M.	NULL
,	NULL
R.	NULL
Conroy	NULL
,	NULL
H.	NULL
E.	NULL
Huber	NULL
,	NULL
P.	NULL
J.	NULL
Goodhart	NULL
,	NULL
A.	NULL
Oliff	NULL
,	NULL
and	NULL
D.	NULL
C.	NULL
Heimbrook	NULL
.	NULL

1993	NULL
.	NULL

Cloning	NULL
and	NULL
characterization	NULL
of	NULL
E2F-2	NULL
,	NULL
a	NULL
novel	NULL
protein	NULL
with	NULL
the	NULL
biochemical	NULL
properties	NULL
of	NULL
transcription	NULL
factor	NULL
E2F	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:7802-7812	NULL
.	NULL

Jacks	NULL
,	NULL
T.	NULL
,	NULL
A.	NULL
Fazeli	NULL
,	NULL
E.	NULL
M.	NULL
Schmitt	NULL
,	NULL
R.	NULL
T.	NULL
Bronson	NULL
,	NULL
M.	NULL
A.	NULL
Goodell	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Weinberg	NULL
.	NULL

1992	NULL
.	NULL

Effects	NULL
of	NULL
an	NULL
Rb	NULL
mutation	NULL
in	NULL
the	NULL
mouse	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
359:295-300	NULL
.	NULL

Johnson	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
W.	NULL
D.	NULL
Cress	NULL
,	NULL
L.	NULL
Jakoi	NULL
,	NULL
and	NULL
J.	NULL
R.	NULL
Nevins	NULL
.	NULL

1994	NULL
.	NULL

Oncogenic	NULL
capacity	NULL
of	NULL
the	NULL
E2F1	NULL
gene	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:12823-12827	NULL
.	NULL

Johnson	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
K.	NULL
Ohtani	NULL
,	NULL
and	NULL
J.	NULL
R.	NULL
Nevins	NULL
.	NULL

1994	NULL
.	NULL

Autoregulatory	NULL
control	NULL
of	NULL
E2F1	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
positive	NULL
and	NULL
negative	NULL
regulators	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

8:1514-1525	NULL
.	NULL

Johnson	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
J.	NULL
K.	NULL
Schwarz	NULL
,	NULL
W.	NULL
D.	NULL
Cress	NULL
,	NULL
and	NULL
J.	NULL
R.	NULL
Nevins	NULL
.	NULL

1993	NULL
.	NULL

Expression	NULL
of	NULL
transcription	NULL
factor	NULL
E2F1	NULL
induces	NULL
quiescent	NULL
cells	NULL
to	NULL
enter	NULL
S	NULL
phase	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
365:349-352	NULL
.	NULL

Kaelin	NULL
,	NULL
W.	NULL
G.	NULL
,	NULL
Jr.	NULL
,	NULL
W.	NULL
Krek	NULL
,	NULL
W.	NULL
R.	NULL
Sellers	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
DeCaprio	NULL
,	NULL
F.	NULL
Ajchenbaum	NULL
,	NULL
C.	NULL
S.	NULL
Fuchs	NULL
,	NULL
T.	NULL
Chittenden	NULL
,	NULL
Y.	NULL
Li	NULL
,	NULL
P.	NULL
J.	NULL
Farnham	NULL
,	NULL
M.	NULL
A.	NULL
Blanar	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1992	NULL
.	NULL

Expression	NULL
cloning	NULL
of	NULL
a	NULL
cDNA	NULL
encoding	NULL
a	NULL
retinoblastoma-binding	NULL
protein	NULL
with	NULL
E2F-like	NULL
properties	NULL
.	NULL

Cell	NULL
70:351-364	NULL
.	NULL

Krek	NULL
,	NULL
W.	NULL
,	NULL
D.	NULL
M.	NULL
Livingston	NULL
,	NULL
and	NULL
S.	NULL
Shirodkar	NULL
.	NULL

1993	NULL
.	NULL

Binding	NULL
to	NULL
DNA	NULL
and	NULL
the	NULL
retinoblastoma	NULL
gene	NULL
product	NULL
promoted	NULL
by	NULL
complex	NULL
formation	NULL
of	NULL
different	NULL
E2F	NULL
family	NULL
members	NULL
.	NULL

Science	NULL
262:1557-1560	NULL
.	NULL

Lam	NULL
,	NULL
E.	NULL
W.	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Watson	NULL
.	NULL

1993	NULL
.	NULL

An	NULL
E2F-binding	NULL
site	NULL
mediates	NULL
cell-cycle	NULL
regulated	NULL
repression	NULL
of	NULL
mouse	NULL
B-myb	NULL
transcription	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:2705-2713	NULL
.	NULL

La	NULL
Thangue	NULL
,	NULL
N.	NULL
B	NULL
.	NULL

1994	NULL
.	NULL

DRTFI/E2F	NULL
:	NULL
an	NULL
expanding	NULL
family	NULL
of	NULL
heterodimeric	NULL
transcription	NULL
factors	NULL
implicated	NULL
in	NULL
cell-cycle	NULL
control	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

19:108-114	NULL
.	NULL

Lee	NULL
,	NULL
E.	NULL
Y.	NULL
,	NULL
C.	NULL
Y.	NULL
Chang	NULL
,	NULL
N.	NULL
Hu	NULL
,	NULL
Y.	NULL
C.	NULL
Wang	NULL
,	NULL
C.	NULL
C.	NULL
Lai	NULL
,	NULL
K.	NULL
Herrup	NULL
,	NULL
W.	NULL
H.	NULL
Lee	NULL
,	NULL
and	NULL
A.	NULL
Bradley	NULL
.	NULL

1992	NULL
.	NULL

Mice	NULL
deficient	NULL
for	NULL
Rb	NULL
are	NULL
nonviable	NULL
and	NULL
show	NULL
defects	NULL
in	NULL
neurogenesis	NULL
and	NULL
haematopoiesis	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
359:288-294	NULL
.	NULL

Lees	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
M.	NULL
Saito	NULL
,	NULL
M.	NULL
Vidal	NULL
,	NULL
M.	NULL
Valentine	NULL
,	NULL
T.	NULL
Look	NULL
,	NULL
E.	NULL
Harlow	NULL
,	NULL
N.	NULL
Dyson	NULL
,	NULL
and	NULL
K.	NULL
Helin	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
retinoblastoma	NULL
protein	NULL
binds	NULL
to	NULL
a	NULL
family	NULL
of	NULL
E2F	NULL
transcription	NULL
factors	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:7813-7825	NULL
.	NULL

Lok	NULL
,	NULL
S.	NULL
,	NULL
K.	NULL
Kaushansky	NULL
,	NULL
R.	NULL
D.	NULL
Holly	NULL
,	NULL
J.	NULL
L.	NULL
Kujjper	NULL
,	NULL
C.	NULL
E.	NULL
Lofton-Day	NULL
,	NULL
P.	NULL
J.	NULL
Oort	NULL
,	NULL
F.	NULL
J	NULL
.	NULL

Grant	NULL
,	NULL
M.	NULL
D.	NULL
Helpel	NULL
,	NULL
S.	NULL
K.	NULL
Burkhead	NULL
,	NULL
J.	NULL
M.	NULL
Kramer	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

Bell	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Sprecher	NULL
.	NULL

1994	NULL
.	NULL

Cloning	NULL
and	NULL
expression	NULL
of	NULL
murine	NULL
thrombopoictin	NULL
cDNA	NULL
and	NULL
stimulation	NULL
of	NULL
platelet	NULL
production	NULL
in	NULL
vivo	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
369	NULL
:	NULL
565-568	NULL
.	NULL

Mudrak	NULL
,	NULL
I.	NULL
,	NULL
E.	NULL
Ogris	NULL
,	NULL
H.	NULL
Rotheneder	NULL
,	NULL
and	NULL
E.	NULL
Wintersberger	NULL
.	NULL

1994	NULL
.	NULL

Coordinated	NULL
frens	NULL
activation	NULL
of	NULL
DNA	NULL
synthesis-	NULL
and	NULL
precursor-producing	NULL
enzymes	NULL
by	NULL
polyomavirus	NULL
large	NULL
T	NULL
antigen	NULL
through	NULL
interaction	NULL
with	NULL
the	NULL
retinoblastoma	NULL
protein	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:1886-1892	NULL
.	NULL

Mudryj	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
W.	NULL
Hiebert	NULL
,	NULL
and	NULL
J.	NULL
R.	NULL
Nevins	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
role	NULL
for	NULL
the	NULL
adenovirus	NULL
inducible	NULL
E2F	NULL
transcription	NULL
factor	NULL
in	NULL
a	NULL
proliferation	NULL
dependent	NULL
signal	NULL
trans-duction	NULL
pathway	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:2179-2184	NULL
.	NULL

Neuman	NULL
,	NULL
E.	NULL
,	NULL
E.	NULL
K.	NULL
Flemington	NULL
,	NULL
W.	NULL
R.	NULL
Sellers	NULL
,	NULL
and	NULL
W.	NULL
G.	NULL
Kaelin	NULL
,	NULL
Jr.	NULL
1994	NULL
.	NULL

Transcription	NULL
of	NULL
the	NULL
E2F-1	NULL
gene	NULL
is	NULL
rendered	NULL
cell	NULL
cycle	NULL
dependent	NULL
by	NULL
E2F	NULL
DNA-binding	NULL
sites	NULL
within	NULL
its	NULL
promoter	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:6607-6615	NULL
.	NULL

Nevins	NULL
,	NULL
J.	NULL
R.	NULL
1992	NULL
.	NULL

E2F	NULL
:	NULL
a	NULL
link	NULL
between	NULL
the	NULL
Rb	NULL
tumor	NULL
suppressor	NULL
protein	NULL
and	NULL
viral	NULL
oncoproteins	NULL
.	NULL

Science	NULL
258:424-429	NULL
.	NULL

Novak	NULL
,	NULL
E.	NULL
K.	NULL
,	NULL
M.	NULL
Reddington	NULL
,	NULL
L.	NULL
Zhen	NULL
,	NULL
P.	NULL
E.	NULL
Sternberg	NULL
,	NULL
C.	NULL
W.	NULL
Jackson	NULL
,	NULL
M.	NULL
P.	NULL
McGarry	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
Swank	NULL
.	NULL

1995	NULL
.	NULL

Inherited	NULL
thrombocytopenia	NULL
caused	NULL
by	NULL
39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

EZ2F-1	NULL
BLOCKS	NULL
TERMINAL	NULL
DIFFERENTIATION	NULL
693	NULL
reduced	NULL
platelet	NULL
production	NULL
in	NULL
mice	NULL
with	NULL
the	NULL
gunmetal	NULL
pigment	NULL
gene	NULL
muta-tion	NULL
.	NULL

Blood	NULL
85:1781-1789	NULL
.	NULL

Odell	NULL
,	NULL
T.	NULL
T.	NULL
,	NULL
and	NULL
C.	NULL
W.	NULL
Jackson	NULL
.	NULL

1968	NULL
.	NULL

Polyploidy	NULL
and	NULL
maturation	NULL
of	NULL
megakaryocytes	NULL
.	NULL

Blood	NULL
32:102-110	NULL
.	NULL

Parker	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
G.	NULL
Eichele	NULL
,	NULL
P.	NULL
Zhang	NULL
,	NULL
A.	NULL
Rawls	NULL
,	NULL
A.	NULL
T.	NULL
Sands	NULL
,	NULL
A.	NULL
Bradley	NULL
,	NULL
E.	NULL
N.	NULL
Olson	NULL
,	NULL
J.	NULL
W.	NULL
Harper	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Elledge	NULL
.	NULL

1995.	NULL
p53-independent	NULL
expression	NULL
of	NULL
p21/cip1	NULL
in	NULL
muscle	NULL
and	NULL
other	NULL
terminally	NULL
differentiating	NULL
cells	NULL
.	NULL

Science	NULL
267	NULL
:	NULL
1024-1027	NULL
.	NULL

Qin	NULL
,	NULL
X.	NULL
Q.	NULL
,	NULL
D.	NULL
M.	NULL
Livingston	NULL
,	NULL
W.	NULL
G.	NULL
Kaelin	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
P.	NULL
D.	NULL
Adams	NULL
.	NULL

1994	NULL
.	NULL

Deregulated	NULL
transcription	NULL
factor	NULL
E2F-1	NULL
expression	NULL
leads	NULL
to	NULL
S-phase	NULL
entry	NULL
and	NULL
p53-mediated	NULL
apoptosis	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:10918-10922	NULL
.	NULL

Ravid	NULL
,	NULL
K.	NULL
,	NULL
D.	NULL
L.	NULL
Beeler	NULL
,	NULL
M.	NULL
S.	NULL
Rabin	NULL
,	NULL
H.	NULL
E.	NULL
Ruley	NULL
,	NULL
and	NULL
R.	NULL
D.	NULL
Rosenberg	NULL
.	NULL

1991	NULL
.	NULL

Selective	NULL
targeting	NULL
of	NULL
gene	NULL
products	NULL
with	NULL
the	NULL
megakaryocyte	NULL
platelet	NULL
factor	NULL
4	NULL
promoter	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:1521-1525	NULL
.	NULL

Robinson	NULL
,	NULL
M.	NULL
O.	NULL
,	NULL
and	NULL
M.	NULL
I.	NULL
Simon	NULL
.	NULL

1991	NULL
.	NULL

Determining	NULL
transcript	NULL
number	NULL
using	NULL
the	NULL
polymerase	NULL
chain	NULL
reaction	NULL
:	NULL
Pgk-2	NULL
,	NULL
mP2	NULL
,	NULL
and	NULL
PGK-2	NULL
transgene	NULL
mRNA	NULL
levels	NULL
during	NULL
spermatogenesis	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:1557-1562	NULL
.	NULL

Robinson	NULL
,	NULL
M.	NULL
O.	NULL
,	NULL
W.	NULL
Zhou	NULL
,	NULL
M.	NULL
Hokum	NULL
,	NULL
D.	NULL
M.	NULL
Danilenko	NULL
,	NULL
R.-Y	NULL
.	NULL

Hsu	NULL
,	NULL
R.	NULL
E.	NULL
Atherton	NULL
,	NULL
W.	NULL
Xu	NULL
,	NULL
S.	NULL
Mu	NULL
,	NULL
C.	NULL
Saris	NULL
,	NULL
S.	NULL
Swift	NULL
,	NULL
G.	NULL
Elliot	NULL
,	NULL
J.	NULL
Del	NULL
Castillo	NULL
,	NULL
P.	NULL
Hunt	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Bosselman	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
tsA58	NULL
simian	NULL
virus	NULL
40	NULL
large	NULL
tumor	NULL
antigen	NULL
disrupts	NULL
megakaryocyte	NULL
differentiation	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:12798-12802	NULL
.	NULL

Sala	NULL
,	NULL
A.	NULL
,	NULL
N.	NULL
C.	NULL
Nicolaides	NULL
,	NULL
A.	NULL
Engelhard	NULL
,	NULL
T.	NULL
Bellon	NULL
,	NULL
D.	NULL
C.	NULL
Lawe	NULL
,	NULL
A.	NULL
Arnold	NULL
,	NULL
X.	NULL
Grana	NULL
,	NULL
A.	NULL
Giordano	NULL
,	NULL
and	NULL
B.	NULL
Calabretta	NULL
.	NULL

1994	NULL
.	NULL

Correlation	NULL
between	NULL
E2F-1	NULL
requirement	NULL
in	NULL
the	NULL
S	NULL
phase	NULL
and	NULL
E2F-1	NULL
transactivation	NULL
of	NULL
cell	NULL
cycle-related	NULL
genes	NULL
in	NULL
human	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

54:1402-1406	NULL
.	NULL

Schulze	NULL
,	NULL
A.	NULL
,	NULL
K.	NULL
Zerfass	NULL
,	NULL
D.	NULL
Spitkovsky	NULL
,	NULL
B.	NULL
Henglein	NULL
,	NULL
and	NULL
D.-P.	NULL
Jansen	NULL
.	NULL

1994	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
E2F	NULL
transcription	NULL
factor	NULL
by	NULL
cyclin	NULL
D1	NULL
is	NULL
blocked	NULL
by	NULL
p16INK4	NULL
,	NULL
the	NULL
product	NULL
of	NULL
the	NULL
putative	NULL
tumor	NULL
suppressor	NULL
gene	NULL
MTS1	NULL
.	NULL

Onco-gene	NULL
9:3475-3482	NULL
.	NULL

Schwarz	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
C.	NULL
H.	NULL
Bassing	NULL
,	NULL
I.	NULL
Kovesdi	NULL
,	NULL
M.	NULL
B.	NULL
Datto	NULL
,	NULL
M.	NULL
Blazing	NULL
,	NULL
S.	NULL
George	NULL
,	NULL
X.	NULL
F.	NULL
Wang	NULL
,	NULL
and	NULL
J.	NULL
R.	NULL
Nevins	NULL
.	NULL

1995	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
E2F1	NULL
transcription	NULL
factor	NULL
overcomes	NULL
type	NULL
beta	NULL
transforming	NULL
growth	NULL
factor-mediated	NULL
growth	NULL
suppression	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:483-487	NULL
.	NULL

Shan	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
W.	NULL
H.	NULL
Lee	NULL
.	NULL

1994	NULL
.	NULL

Deregulated	NULL
expression	NULL
of	NULL
E2F-1	NULL
induces	NULL
S-phase	NULL
entry	NULL
and	NULL
leads	NULL
to	NULL
apoptosis	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:8166-8173	NULL
.	NULL

Shan	NULL
,	NULL
B.	NULL
,	NULL
X.	NULL
Zhu	NULL
,	NULL
P.	NULL
L.	NULL
Chen	NULL
,	NULL
T.	NULL
Durfee	NULL
,	NULL
Y.	NULL
Yang	NULL
,	NULL
D.	NULL
Sharp	NULL
,	NULL
and	NULL
W.	NULL
H.	NULL
Lee	NULL
.	NULL

1992	NULL
.	NULL

Molecular	NULL
cloning	NULL
of	NULL
cellular	NULL
genes	NULL
encoding	NULL
retinoblastoma-associ-ated	NULL
proteins	NULL
:	NULL
identification	NULL
of	NULL
a	NULL
gene	NULL
with	NULL
properties	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
E2F	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:5620-5631	NULL
.	NULL

Shivdasani	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
M.	NULL
F.	NULL
Rosenblatt	NULL
,	NULL
D.	NULL
Zucker-Franklin	NULL
,	NULL
C.	NULL
W.	NULL
Jackson	NULL
,	NULL
P.	NULL
Hunt	NULL
,	NULL
C.	NULL
J.	NULL
M.	NULL
Saris	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Orkin	NULL
.	NULL

1995	NULL
.	NULL

Transcription	NULL
factor	NULL
NF-E2	NULL
is	NULL
required	NULL
for	NULL
platelet	NULL
formation	NULL
independent	NULL
of	NULL
the	NULL
actions	NULL
of	NULL
thrombopoi-etin/MGDF	NULL
in	NULL
megakaryocyte	NULL
development	NULL
.	NULL

Cell	NULL
81:695-704	NULL
.	NULL

Singh	NULL
,	NULL
P.	NULL
,	NULL
S.	NULL
H.	NULL
Wong	NULL
,	NULL
and	NULL
W.	NULL
Hong	NULL
.	NULL

1994	NULL
.	NULL

Overexpression	NULL
of	NULL
E2F-1	NULL
in	NULL
rat	NULL
embryo	NULL
fibroblasts	NULL
leads	NULL
to	NULL
neoplastic	NULL
transformation	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:3329-3338	NULL
.	NULL

Skapek	NULL
,	NULL
S.	NULL
X.	NULL
,	NULL
J.	NULL
Rhee	NULL
,	NULL
D.	NULL
B.	NULL
Spicer	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Lassar	NULL
.	NULL

1995	NULL
.	NULL

Inhibition	NULL
of	NULL
myogenic	NULL
differentiation	NULL
in	NULL
proliferating	NULL
myoblasts	NULL
by	NULL
cyclin	NULL
D1-dependent	NULL
kinase	NULL
.	NULL

Science	NULL
267:1022-1024	NULL
.	NULL

Slansky	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Y.	NULL
Li	NULL
,	NULL
W.	NULL
G.	NULL
Kaelin	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farnham	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
protein	NULL
synthesis-dependent	NULL
increase	NULL
in	NULL
E2F1	NULL
mRNA	NULL
correlates	NULL
with	NULL
growth	NULL
regulation	NULL
of	NULL
the	NULL
dihydrofolate	NULL
reductase	NULL
promoter	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:1610-1618	NULL
.	NULL

Surh	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
and	NULL
J.	NULL
Sprent	NULL
.	NULL

1994	NULL
.	NULL

T-cell	NULL
apoptosis	NULL
detected	NULL
in	NULL
sife	NULL
during	NULL
positive	NULL
and	NULL
negative	NULL
selection	NULL
in	NULL
the	NULL
thymus	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
372:100-103	NULL
.	NULL

Szekely	NULL
,	NULL
L.	NULL
,	NULL
W.	NULL
Q.	NULL
Jiang	NULL
,	NULL
F.	NULL
Bulic	NULL
Jakus	NULL
,	NULL
A.	NULL
Rosen	NULL
,	NULL
N.	NULL
Ringertz	NULL
,	NULL
G.	NULL
Klein	NULL
,	NULL
and	NULL
K.	NULL
G.	NULL
Wiman	NULL
.	NULL

1992	NULL
.	NULL

Cell	NULL
type	NULL
and	NULL
differentiation	NULL
dependent	NULL
heterogeneity	NULL
in	NULL
retinoblastoma	NULL
protein	NULL
expression	NULL
in	NULL
SCID	NULL
mouse	NULL
fetuses	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

3:149-156	NULL
.	NULL

Wiman	NULL
,	NULL
K.	NULL
G.	NULL
1993	NULL
.	NULL

The	NULL
retinoblastoma	NULL
gene	NULL
:	NULL
role	NULL
in	NULL
cell	NULL
cycle	NULL
control	NULL
and	NULL
cell	NULL
differentiation	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

7:841-845	NULL
.	NULL

Wu	NULL
,	NULL
X.	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Levine	NULL
.	NULL

1994	NULL
.	NULL

E2F-1	NULL
and	NULL
p53	NULL
cooperate	NULL
to	NULL
mediate	NULL
apoptosis	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:3602-3606	NULL
.	NULL

Xu	NULL
,	NULL
G.	NULL
,	NULL
D.	NULL
M.	NULL
Livingston	NULL
,	NULL
and	NULL
W.	NULL
Krek	NULL
.	NULL

1995	NULL
.	NULL

Multiple	NULL
members	NULL
of	NULL
the	NULL
E2F	NULL
transcription	NULL
factor	NULL
family	NULL
are	NULL
the	NULL
products	NULL
of	NULL
oncogenes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:1357-1361	NULL
.	NULL

PES2	NULL
w.t	NULL
.	NULL

PBE82	NULL
ow.t	NULL
.	NULL

PE42	NULL
”	NULL
£50	NULL
PESO	NULL
PES	NULL
P	NULL
}	NULL
.	NULL

f.	NULL
{	NULL
#	NULL
.	NULL

§	NULL
Em	NULL
:	NULL
180	NULL
e.	NULL
©	NULL
G	NULL
&	NULL
*	NULL
9	NULL
&	NULL
5	NULL
;	NULL
v	NULL
®	NULL
vae	NULL
'	NULL
a	NULL
'	NULL
0,0	NULL
aM	NULL
»	NULL
1	NULL
|	NULL
ent	NULL
easing	NULL
a	NULL
»	NULL
C	NULL
®	NULL
£95	NULL
u	NULL
y	NULL
!	NULL

partie	NULL
ites	NULL
f	NULL
”	NULL
ii	NULL
“	NULL
Lavid	NULL
23	NULL
ag	NULL
‘	NULL
033	NULL
.	NULL

#	NULL
5	NULL
.	NULL

``	NULL
is	NULL
i	NULL
oh	NULL
G	NULL
m	NULL
pauls	NULL
viet	NULL
)	NULL
ay	NULL
ack	NULL
me	NULL
,	NULL
on	NULL
R	NULL
u	NULL
'	NULL
w	NULL
!	NULL

$	NULL
.l	NULL
‘	NULL
£	NULL
'	NULL
tht	NULL
&	NULL
``	NULL
I	NULL
&	NULL
b	NULL
Pt	NULL
?	NULL

*t	NULL
w	NULL
in	NULL
Fpl	NULL
4	NULL
/	NULL
*	NULL
$	NULL
wal	NULL
6	NULL
,	NULL
m	NULL
a	NULL
»	NULL
{	NULL
39	NULL
A	NULL
_u	NULL
'	NULL
h	NULL
‘	NULL
:	NULL
Mery	NULL
#	NULL
,	NULL
,	NULL
*s	NULL
“	NULL
ﬂ	NULL
.	NULL

-	NULL
‘	NULL
\	NULL
“	NULL
'	NULL
3	NULL
:	NULL
.n	NULL
4:3_i	NULL
ﬁg	NULL
}	NULL
...	NULL
5	NULL
:	NULL
%	NULL
esis	NULL
446	NULL
;	NULL
-	NULL
f	NULL
uZ..	NULL
&	NULL
a	NULL
$	NULL
132	NULL
.	NULL

1	NULL
ﬁaj	NULL
‘	NULL
“	NULL
T	NULL
‘	NULL
,	NULL
v.	NULL
o	NULL
a	NULL
%	NULL
ﬁdiﬂg	NULL
aw	NULL
tor	NULL
“	NULL
a	NULL
,	NULL
“	NULL
a	NULL
a	NULL
shal	NULL
s.	NULL
S	NULL
gx	NULL
e=so	NULL
a	NULL
%	NULL

